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ABSTRACT
REGULATION OF SPARC GENE EXPRESSION BY THE ACTIVATOR PROTEIN 1
TRANSCRIPTION FACTOR
Joseph William Briggs
Old Dominion University, 2005
Chair: Dr. Timothy J. Bos

Overexpression of the c-Jun proto-oncogene in MCF7 breast cancer cells results
in a variety of phenotypic changes related to malignant progression including a shift to
estrogen independent growth, increased cell motility and invasion. Concurrent with these
phenotypic changes are alterations to cellular gene expression patterns. One gene that
becomes highly upregulated is SPARC (secreted protein acidic and rich in cysteine).
Increased SPARC expression is associated with malignant progression in a variety of
different cancers, although little is known regarding the mechanisms of SPARC gene
regulation. Therefore, the objectives of this study were: 1.) to determine the mechanisms
by which c-Jun regulates SPARC gene expression, and 2.) to determine the contribution
of SPARC to c-Jun induced phenotype in a MCF7 breast cancer model system.
In order to determine the role of SPARC in c-Jun mediated oncogenic
progression, we over-expressed SPARC in MCF7 cells and blocked its expression in the
c-Jun/MCF7 cell line. We found that antisense mediated suppression of SPARC
dramatically inhibits both cell motility and invasion in this c-Jun/MCF7 model. In
contrast, stable overexpression of SPARC in the parental MCF7 cell line was not
sufficient to stimulate cell motility or invasion suggesting that SPARC cooperates with
other c-Jun target genes to establish a pro-invasive phentoytpe.
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In order to determine the mechanism(s) of c-Jun induced SPARC gene activation,
we started by analyzing DNA binding and transactivation using the human SPARC
promoter. The activity of the full-length SPARC promoter (-1409/+28) was 15-30 fold
higher in c-Jun over-expressing cells compared to vector control cells. Promoter deletion
analysis revealed that a region between -120 and -70 conferred c-Jun responsiveness.
This region does not contain an AP-1 binding site, but does contain a GC rich element
which is recognized in vitro and in vivo by Spl. Importantly, chromatin
immunoprecipitation analysis demonstrated that c-Jun is physically associated with the
SPARC proximal promoter region during gene activation.
Further analysis of the SPARC promoter sequence, including the c-Jun responsive
region, revealed the presence of multiple CpG sequences. Methylation of cytosine
residues in a CpG context has been shown to inhibit gene expression. Therefore, we
examined the contribution of DNA methylation to SPARC gene regulation. Analysis of
MCF7 cells, in which SPARC expression is undetectable, revealed methylation of the
SPARC promoter at both distal and proximal sites. Inhibition of DNA methyltransferase
activity in these cells resulted in a dose dependent increase in SPARC mRNA levels
suggesting that SPARC may be transcriptionally repressed via DNA methylation in
MCF7 cells. Interestingly, overexpression of c-Jun cells resulted in a localized
demethylation of the SPARC promoter near the transcription start site correlating with an
increase in SPARC mRNA and protein levels. Transfection of an in vitro methylated
SPARC promoter/reporter plasmid into c-Jun/MCF7 cells resulted in a dramatic decrease
in promoter activity suggesting an important functional role for SPARC promoter
methylation in regulating c-Jun responsiveness.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Additional characterization of the SPARC promoter revealed changes in posttranslational modification of histone H3 and H4 known to be associated with chromatin
remodeling and gene activation. Specifically, chromatin immunoprecipitation analysis
demonstrated hyperacetylation of histones as well as enrichment of methylated histone
H3 at lysine 4 in response to c-Jun.
In conclusion, our results support a model where c-Jun acts as a molecular switch
directing site-specific epigenetic changes leading to SPARC gene activation. Moreover,
we have identified SPARC as an important c-Jun target gene which contributes to
phenotypic progression in an MCF7 model system.
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1

CHAPTER I
INTRODUCTION

A. Breast Cancer Biology and Epidemiology

Breast cancer is a major health problem in the United States and worldwide. It is
estimated that 211,240 new cases of invasive breast cancer will be diagnosed in 2005 and
that 40,410 women in the United States will die from this disease this year (1). Breast
cancer is the third most common cause of death in women 40-55 years of age and the
incidence of disease increases with age. More than 94% of new cases and 96% of deaths
attributed to breast cancer occur in women ages 40 and older (1). Success in treating the
disease relies, in large part, on early diagnosis and appropriate therapeutic intervention
prior to spread of the disease. The five-year survival rate for patients diagnosed with
only localized tumor involvement is 97% (1). This number drops to 78% when there is
regional spread of the disease (1). Patients diagnosed late in disease progression, in
which the tumor has spread to secondary organ systems, have only a 23% five-year
survival rate (1).

B. The Etiology of Breast Cancer

It is widely accepted that breast cancer, like other neoplasms, is the result of
genetic alterations which lead to aberrant cell growth (2-5). Greater than 90% of breast
cancers arise from cells of epithelial origin (6). Breast malignancies are categorized
based on the type of tissue from which they arise. The two most common types are

This dissertation follows the format of the journal Cancer Research.
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ductal (tissue connecting the milk glands and nipple) carcinomas and lobular (milk
producing glandular tissue) carcinomas. Tumors can further be classified based on cell
genotype and phenotype. Mutations in the breast cancer associated genes BRCA1 and
BRCA2 are associated with familial forms of breast cancer (3,7). However, these cases
comprise only a small portion of the total number of breast cancer cases diagnosed each
year (8, 9). More frequently, the underlying cause of sporadic breast tumors is not
known. Other genetic alterations which have been shown to occur in the more frequent,
sporadic cases of breast cancer include: gene mutations, gene amplifications, gene
deletions and/or genetic rearrangements (10-13). For example, mutation of the p53 tumor
suppressor gene has been demonstrated in approximately 25% of breast tumors (14, 15).
In addition, amplification of the MYC proto-oncogene occurs in 15-20% of breast cancers
(16, 17). Finally, amplification of the HER2/neu gene has been shown in 25-30% of
breast neoplasms (17-19).
In addition to gene copy number differences, altered gene expression is a common
occurrence in breast cancer. A study comparing the gene expression profiles of normal
mammary epithelial cells to invasive breast cancer cells revealed differences in gene
expression patterns between the two cell populations (20). It is believed that some of
these differentially regulated genes are involved in breast cancer progression from a
benign to a malignant state. Differential expression of genes such as estrogen receptor
alpha, HER2!neu and the proto-oncogene JUN are well documented (21-26). These
observations have led to the understanding that the cellular gene expression profile
ultimately determines cell phenotype. This knowledge has been used to develop new
treatment regimes for breast cancer and to identify biomarkers for use as prognostic
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indicators. For example, estrogen receptor positive tumors respond to the growth
inhibitory effects of the anti-estrogen, tamoxifen (27). Likewise, the growth of breast
tumors with elevated levels of the HER2lneu gene product is inhibited by the monoclonal
antibody trastuzumab (28).
Our current understanding of breast cancer progression is that it is a multi-step
process consisting of the initiating oncogenic event(s) followed by promotion of tumor
cell growth and finally, disease progression (2, 29). These step-wise alterations have
been characterized histopathologically and phenotypically as 1.) normal mammary
epithelial cell 2.) benign hyperplasia 3.) carcinoma in situ 4.) locally invasive and 5.)
metastatic carcinoma. The conversion from benign to malignant neoplasia is
characterized by an invasive cellular phenotype where cells become motile and degrade
the local extracellular matrix and basement membrane (30-34). These phenotypes are not
characteristic of normal epithelial cells, but rather cells of mesenchymal origin. This
phenomenon has been described as “epithelial-to-mesenchymal transition” (35). This is
considered an important event in the “evolution” of a tumor cell because it represents a
time when the phenotype has been sufficiently altered resulting in pathology. This
pathology involves disruption of the normal tissue architecture, disruption of the
basement membrane, trauma, and inflammation. A subset of locally invasive cells may
disseminate into the lymphatics and vasculature of the breast. An even smaller portion of
the cells which enter the circulation (<0.01%) result in the formation of metastatic foci
(36). Metastasis is defined as establishment of the tumor in a secondary organ system,
discontinuous from the primary lesion (1). This event is important because the majority
of morbidity and mortality associated with breast cancer is the result of metastatic

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

4
disease. However, the cellular events required for malignant progression remain a
mystery.
In order to better understand the molecular mechanisms of breast cancer
progression it would be of use to identify genes which play a functional role in the
disease process. As a result there has been an effort to identify and validate functional
genes as opposed to bystander genes. Along these same lines, it is of interest to better
understand how expression of these genes is regulated in non-invasive versus invasive
tumor cells.
A number of studies have demonstrated that the proto-oncogene JUN may play an
important role in oncogenesis and tumor progression. For example, overexpression of
c-Jun has been shown to induce cell transformation in primary chicken embryo
fibroblasts and, in cooperation with oncogenic Ras, to transform primary rat cells (3743). Importantly, c-Jun expression is increased in primary and metastatic breast tumor
samples when compared to normal breast epithelial cells (25, 44, 45). Patients with c-Jun
positive breast tumors are also less responsive to tamoxifen therapy and have shorter
survival rates (45). In support of these observations, there is an inverse correlation
between c-Jun expression and estrogen receptor status (44-46). Interestingly, to date,
there have been no reports of JUN gene amplification or mutation. However, several
studies have demonstrated an increase in c-Jun expression and/or c-Jun DNA binding and
related transcriptional activity (25, 47-49). The current paradigm is that c-Jun acts at the
level of transcriptional transactivation to “turn-on” and/or “tum -off ’ a subset of genes
involved in regulating cell phenotype.
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In addition to c-Jun, other members of the AP-1 transcription factor family have
been implicated in breast cancer. For example, increased expression of c-Fos correlates
with failure to respond to endocrine therapy and poor survival (45). In addition, Fra-1
expression is high in invasive breast cancer cell lines and its expression correlates with
estrogen receptor negative breast tumors (44, 50, 51). Interestingly, we and others, have
shown that FRA1 is a c-Jun target gene (50, 51). In contrast, JunB expression is
decreased in the invasive breast cancer cell line MDA-MB-231 compared to less invasive
cell lines (20). Increased FosB expression correlates with well differentiated, estrogen
receptor positive tumors (44). Finally, a comparison of gene expression patterns from 13
different breast cancer cell lines revealed dramatically elevated expression of both c-Jun
and Fra-1, primarily in the highly invasive lines (20).

C. Properties and Functions of the Transcription Factor c-Jun

The Jun oncoprotein was originally identified as the Avian Sarcoma Virus 17
gene product responsible for viral induced cell transformation (52). Subsequent studies
demonstrated the existence of a cellular counterpart to viral Jun, and was termed c-Jun
(53). c-Jun belongs to the superfamily of bZIP (basic region leucine zipper) proteins
which are known as transcriptional regulators (54, 55). Within the bZIP family c-Jun is
the proto-type for the activator protein-1 (AP-1) transcription factor family (53). The
JU N gene is evolutionarily conserved in organisms from Drosophila to humans. In
humans, JUN is a single copy gene located on chromosome lp 3 1-32. JUN encodes a
39kDa protein which is required for normal embryonic development. This is supported
by observations that JUN -/- (null) mice exhibit embryonic lethality (56, 57).
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c-Jun has been shown to contain distinct modular domains involved in
transactivation, dimerization and DNA binding (Fig. 1) (53, 54, 58). Under normal
physiological conditions, c-Jun expression follows immediate-early kinetics in response
to mitogenic stimuli as well as stress activated cell signaling (55, 59, 60). In addition,
c-Jun is rapidly induced in cells following treatment with the tumor promoting agent,
phorbol ester (55, 59-61). This activation of c-Jun expression has been shown to occur as
a result of protein kinase C signaling events (55, 59-61). In NIH3T3 cells, c-jun mRNA
levels increase as early as 30 minutes following serum stimulation and return to basal
levels after approximately two hours (62). The half-life of the c-jun message is regulated
by the presence of AU rich mRNA destabilizing elements in the 3’ untranslated region
(63). Furthermore, c-Jun protein undergoes rapid turnover mediated by a proteolytic
signal PEST amino acid sequence (64, 65). However, during pathological conditions,
such as tumorigenesis, c-Jun expression and/or steady-state levels has been shown to be
increased (25, 45, 66, 67).
The c-Jun protein is capable of forming dimers with members of the Jun (c-Jun,
Jun B, Jun D), Fos (c-Fos, Fra 1, Fra 2, Fos B), ATF/CREB (ATF2, ATF3), and Maf/Nrl
families through a common leucine zipper motif (54, 68-73). This prerequisite
dimerization affects DNA binding affinity and site recognition as well as transactivation
potential (54, 71-73). For example, Jun/Fos heterodimers form stronger interactions than
Jun/Jun homodimers and in vitro synthesized Jun proteins exhibit lower affinity binding
to AP-1 sequences than if mixed with c-Fos (74-76). As a result, it is widely accepted
that the relative abundance of AP-1 proteins determines the identity of AP-1 dimer
combinations and the cellular profile of genes they regulate.
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A
c-Jun Protein Modular Domain Structure

transactivation domain

±
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Fig. 1. c-Jun and the AP-1 transcription factor family members. A, Schematic
representation of the c-Jun protein modular domain architecture. B, Summary of Jun
and Fos gene family members.
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In the direct model of AP-1 regulated gene expression, AP-1 dimeric complexes
recognize and bind the consensus DNA sequence TGAC/GTCA in the promoters and
enhancers of target genes (72-74, 77, 78). The specificity of DNA binding is determined
by positively charged amino acids in the basic region, adjacent to the leucine zipper
dimerization domain (69). However, AP-1 is fairly promiscuous and recognizes
numerous non-canonical variations of this site as well as variations of the eight base pair
consensus binding site for the ATF/CREB proteins, TGACGTCA (79-81). For instance,
c-Jun/ATF2 will bind to the AP-1 site in the urokinase plasminogen activator promoter
with the sequence TGAAGTCA with high affinity (82). In contrast, c-Jun/c-Fos
heterodimers do not bind well to this sequence and c-Jun homodimers do not bind at all
(82). The AP-1 like site in the proenkephalin enhancer, TGCGTCA, binds well to JunD
but not to JunB homodimers (83). We have demonstrated similar qualitative sequence
specificity differences for variations of AP-1 and CREB target sequences between v-Jun
and c-Jun isolated from chicken embryo fibroblasts (80). The existence of both high and
low affinity AP-1 binding sites has important gene regulatory implications. Specifically,
target gene regulation by AP-1 proteins depends not only on binding site context but also
on the levels of specific AP-1 dimers expressed at any given time. Taken together, these
studies demonstrate the capability for unique gene target regulation based on the
compositional properties of AP-1 dimers. It is these gene regulatory patterns, which
ultimately influence the biological phenotype.
In addition to these direct mechanisms of transcriptional control, c-Jun/AP-1 can
also influence gene regulation through indirect mechanisms by interacting with other
sequence specific transcription factors (84-91). For example, c-Jun has been shown to
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interact with the Spl transcription factor to regulate expression of the p 2i WAF1/c‘PI and
12(S)-lipoxygenase genes (92, 93). In these examples, c-Jun mediated transcriptional
activation was shown to be independent of binding to an AP-1 DNA element (92, 93).
c-Jun has also been shown to interact with the retinoblastoma (RB) protein resulting in
synergistic activation of the DNA methyltransferase gene, DNMT1. However, in this
example a consensus AP-1 site in the DNMT1 promoter was required for c-Jun mediated
transactivation (94). Additionally, c-Jun has been shown to utilize non-canonical AP-1
sites such as one present in the multi-drug resistance gene, MDR1, as a means of
regulating gene transcription (95). Mutation of the MDR1 AP-1 like site from
TCAGTCA to a consensus site (TGAGTCA) resulted in increased promoter activity in
MCF7 cells transiently transfected with c-Jun (95).
But how does c-Jun promote transcription activation? The current paradigm is
that c-Jun binds DNA in a sequence specific manner and interacts with components of the
basal transcription machinery and co-activators to stabilize the transcription pre-initiation
complex (PIC). In support of this, c-Jun has interacts with TAF1 and TFIIB (96-98).
Furthermore, c-Jun mediated transcription is dependent on transcription associated
factors (TAFs) in vitro (97). Interaction with co-activators such as CBP (cyclic AMP
responsive element binding protein) leads to chromatin remodeling due to CBP’s intrinsic
histone acetyltransferase activity (99, 100). As a result, it is believed that these events
lead to increased chromatin accessibility and long term potentiation of transcription by
directing chromatin modification at a target locus.
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D. The MCF7 Breast Cancer Model System

In order to study the role of c-Jun in breast cancer progression, our laboratory has
previously shown that c-Jun enhances tumorigenicity of the human mammary carcinoma
cell line, MCF7 (46). These changes include a shift to estrogen independent growth,
increased in vitro cell motility and invasion and increased tumor formation in
ovariectomized athymic (nude) mice (Fig. 2) (46). These changes are specific to c-Jun as
demonstrated by comparing MCF7 stable cell lines overexpressing c-Jun or the related
JUN family member, JunD. JunD/MCF7 cells fail to exhibit phenotypic changes
consistent with malignant progression (Appendix A, Fig. 38). In addition, nuclear
extracts isolated from c-Jun/MCF7 cells demonstrate increased AP-1 DNA binding
activity compared to JunD/MCF7 or empty vector control/MCF7 stable cell lines
(Appendix A, Fig. 39). Consistent with this observation, we found that overexpression of
c-Jun induces a number of changes in gene expression including upregulation of the
mesenchymal cell marker, vimentin, and downregulation of estrogen receptor alpha (Fig.
2) (46, 51). In addition, analysis of the AP-1 expression profile in c-Jun/MCF7 cells,
compared to JunD/MCF7 and vector control/MCF7 cells, reveals changes consistent with
those observed in clinical tumors (44). These changes include upregulation of Fra-1 and
FosB and downregulation of JunB (Fig. 3). Taken together, these studies establish that
the c-Jun/MCF7 cell culture model provides a useful tool in which to study mechanisms
involved in breast cancer development and progression.
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List of c-Jun Target Genes in MCF7 Breast Cancer Cells
Upregulated
1.)
2.)
3.)
4.)
5.)

Downregulated

Cytokeratin 7
EMMPR1N
Fibronectin
Metallothionein III
MMIF

1.) GADD 153
2.) p21WAF1/Cipl

3.) Cytokeratin 19
4.) TRIP6
5.) Estrogen receptor alpha

6.) p 16INK4a
7.) PAI-1
8.) SPARC
9.) TIMP-1
10.) Vimentin
B

Summary of c-Jun Induced Phenotypic Changes in MCF7 Cells
phenotype

empty vector control/MCF7
stable cell lines

c-Jun/MCF7 stable cell lines

cell morphology

tight junctions, adherent

large, less adherent,
less compact growth

responsiveness to estrogen

yes

no

growth doubling time

faster, except in estrogen
depleted medium

slower

tumorigenicity in nude mice

0/18

13/18

cell motility and chemotaxis

weak

strong

Matrigel™ invasion

weak

strong

Fig. 2. Summary of c-Jun induced changes in gene expression and
phenotype in MCF7 cells. A, A list of genes up or down regulated in
response to constitutive overexpression of c-Jun in MCF7 cells. B, A
summary of phenotypic changes in c-Jun/MCF7 cells compared to empty
vector control/MCF7 stable cell lines.
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Fig. 3. Expression profile of JUN and FOS family genes in MCF7,
JunD/MCF7 and c-Jun/MCF7 stable cell lines. Semi-quantitative RT-PCR
analysis of endogenous AP-1 mRNA levels in the presence or absence of c-Jun
or JunD overexpression in MCF7 cells. The numbers (1) and (2) denote
individual stable cell lines tested. 18S serves as an invariantly expressed internal
control gene. (L) denotes DNA molecular weight marker.
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E. Properties and Functions of SPARC

One of the genes most highly upregulated by c-Jun in MCF7 breast cancer cells is
SPARC (secreted protein acidic and rich in cysteine) (51). An analysis of SPARC
expression by semi-quantitative RT-PCR demonstrated a >100 fold increase in steady
state mRNA levels (Fig. 4). SPARC, also known as osteonectin and BM-40, belongs to
the matricellular family of proteins which are involved in mediating interactions between
the cell and extracellular matrix (101-107). The SPARC gene is evolutionarily conserved
from C. elegans to humans and was originally identified as a glycoprotein constituent of
bovine bone (108-110). Structural and functional analysis demonstrated the existence of
several modular domains including: 1.) an amino-terminal acidic domain which has
been shown to bind calcium 2.) a follastatin-like domain containing a copper binding
region and promotes angiogenesis 3.) a carboxy terminal E-F hand domain which
consists of a second calcium binding region (111). Additional studies have demonstrated
the potential for differential N-linked glycosylation patterns depending on the cell type
analyzed (112). In platelets, SPARC contains mainly complex type sugars, whereas in
bone, SPARC contains primarily high mannose type (112). The functional significance
of this differential glycosylation is unknown.
Expression of SPARC has been demonstrated in a wide range of tissues and is
increased in epithelial cells during the processes of tissue remodeling and tumorigenesis
(107, 108, 113, 114). SPARC is secreted from cells and binds to proteins such as
collagen, thrombospondin, platelet derived growth factor (PDGF) receptor and vascular
endothelial growth factor (VEGF) receptor (115-117). The normal physiological role for
SPARC has been demonstrated during the processes of wound healing, morphogenesis
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A

semi-quantitative RT-PCR
MCF7
1
.01
L
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I

c-Jun/MCF7
1
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input RNA(ug)
L
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SPARC

i
B
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Western blot: anti-SPARC antibody
MCF7
1 2
3

1

c-Jun/MCF7
2
3

independent stable cell clones
■M-

SPARC protein

*equal protein (ug) loading

Fig. 4. Analysis of SPARC expression in MCF7 and c-Jun/MCF7 cells. A, RTPCR analysis demonstrating steady state levels of SPARC RNA expression using
18S as an internal control. B, Western blot showing expression of the 43kDa
glycosylated form of SPARC protein. Equal amounts of total protein (50pg) were
loaded in each lane.
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and bone formation (102). SPARC inhibits cell adhesion resulting in perturbed cell-tocell contacts (101, 102). These observations are likely a result of decreased focal
adhesion contacts during conditions when SPARC is highly expressed (103, 118, 119).
In addition, overexpression of SPARC has been shown to inhibit cell cycle progression
by initiating Gi arrest in some cell types (102).
A multitude of studies have been conducted in which differences in SPARC gene
expression correlate with tumor formation and/or progression. For example, SPARC
mRNA and protein levels are increased in metastatic prostate cancer cells when
compared to primary tumor cells (120). In addition, in well-differentiated brain
astrocytoma tumors SPARC expression is increased (121). Furthermore, increased
expression of SPARC has been demonstrated in bladder cancer and hepatocellular
carcinoma and is associated with poor prognosis and late stage disease (122, 123). A
clinical study of patients with melanoma demonstrated that SPARC expression was
elevated in primary and metastatic forms of the disease (124, 125). Importantly, specific
inhibition of SPARC in malignant melanoma cells abolished in vivo tumorigenicity in a
mouse model (126). Immunohistochemical analysis of invasive meningioma and breast
tumor samples revealed an increase in SPARC protein when compared to benign tissue
(127, 128). Interestingly, increased SPARC expression has been observed in conjunction
with increased c-Jun and Fra-1 expression in a panel of invasive breast cancer cell lines
(20). Taken together, these studies suggest that increased SPARC may play a role in
tumor cell progression.
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F. Regulation of SPARC Gene Expression

While there is an abundance of evidence emphasizing the importance of SPARC
expression in numerous cancer model systems, we know very little with regards to basic
mechanisms of SPARC gene regulation. The human SPARC promoter was originally
isolated and shown to be active in transient transfection assays in HT1080 human
fibrosarcoma cells and HeLa cervical carcinoma cells when inserted upstream of a
luciferase reporter gene (129). Initial experiments characterizing the chicken SPARC
promoter established Jun responsiveness in chicken embryo fibroblasts (130).
Interestingly, in these cells, endogenous chicken SPARC is normally expressed, but
becomes downregulated in response to v-Jun expression. This v-Jun mediated repression
of SPARC was shown to contribute to transformation of chicken embryo fibroblasts in
vitro and fibrosarcoma formation in vivo (42). Conversely, we have shown that
overexpression of c-Jun in MCF7 breast cancer cells results in SPARC gene activation,
increased cell motility and invasion (46, 131). This interesting paradox regarding
SPARC expression and regulation by v-Jun and c-Jun likely reflects cell type specific
and/or species specific differences, but nonetheless, emphasizes the relationship between
c-Jun expression and SPARC gene regulation.

G. Hypothesis and Specific Aims

Increased c-Jun/AP-1 expression is associated with breast cancer progression to a
more invasive, hormone independent phenotype. However, the mechanisms by which
c-Jun contributes to tumor progression remain unclear. Because c-Jun is a transcription
factor, it is widely accepted that deregulated expression of c-Jun target genes plays a role
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in this process. One intriguing c-Jun target gene shown to be upregulated in our MCF7
model system was SPARC. Increased SPARC expression is associated with
tumorigenesis and malignant progression in a variety of cancers. Therefore, the
objectives of this dissertation were to: 1.) determine the mechanisms by which c-Jun
regulates SPARC gene expression, and 2.) determine the contribution of SPARC to c-Jun
induced phenotype in a MCF7 breast cancer model system. Characterization of the
events is critical in order to better understand the process of c-Jun mediated gene
regulation during phenotypic progression. Our hypothesis was that c-Jun binds to
SPARC gene regulatory regions leading to an increase in SPARC expression and a
concomitant change to a pro-invasive cell phenotype. To test our hypothesis we
proposed the following three specific aims:

Aim 1. To determine the effects of SPARC gene expression on MCF7 cell phenotype.

Aim 2. To map the c-Jun responsive region(s) of the human SPARC gene promoter.

Aim 3. To analyze epigenetic modifications associated with SPARC gene expression.
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CHAPTER II
MATERIALS AND METHODS

Cells used in these studies

The c-Jun/MCF7 stable cell lines and empty vector control/MCF7 cell lines were
a generous gift from Dr. Mike Birrer (National Institutes of Health/National Cancer
Institute). Cell lines were maintained in a humidified chamber at 37°C and 5% carbon
dioxide in Improved Minimal Essential Medium with zinc option (Mediatech
Incorporated, Herndon, VA) supplemented with 10% fetal bovine serum and 1%
penicillin/ streptomycin.

Large scale preparation of plasmid DNA

Large scale preparation of plasmid DNA was done using the Qiagen High-Speed
Midiprep Kit (Qiagen Corporation, Valencia, CA) according to manufacturer’s
instructions.

Cloning of the human SPARC protein coding region

Total RNA was isolated from c-Jun/MCF7 cells using TRIZOL® reagent
(Invitrogen Corporation) according to manufacturer’s recommendations. lOOng of total
RNA was reverse transcribed using Moloney Murine Leukemia Virus reverse
transcriptase (Promega Corporation) and random hexamers. The human SPARC protein
coding region was amplified from the cDNA synthesis reaction using the Advantage™ 2
PCR kit (Clontech Corporation) using the following primers: SPARC cloning primer 1=
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5’ gtcagaagcttatgagggcctggatcttctttctcc 3’, SPARC cloning primer 2= 5’
gtcagatcgattggatttagatcacaagatccttgtcg 3’. SPARC cloning primer 1 has a Hindlll site
incorporated at the 5 ’ end to facilitate subsequent cloning while SPARC cloning primer 2
has a Clal site at its 5’ end. Thermocycling conditions for SPARC amplification were as
follows: step 1, 95°C for 2 minutes, step 2, 95°C for 30 seconds, step 3, 68°C for 30
seconds, step 4, 68°C for 1 minute, repeat steps 2-4, 29 times. The resultant PCR product
is expected to be 944 base pairs consisting of 912 bases corresponding to the human
SPARC coding region. PCR products were resolved by electrophoresis on a 1% low
melting point agarose/IX TBE gel stained with GelStar® reagent (Cambrex Corporation,
East Rutherford, NJ) at a final concentration of IX for visualization. The SPARC
amplicon was purified using the Qiaquick Gel Extraction Kit (Qiagen Corporation,
Valencia, CA) following manufacturer’s recommendations. This purified RT-PCR
product was digested with Hindlll and Clal restriction enzymes and ligated to a similarly
digested pGEM-7Zf+ plasmid (Promega Corporation, Madison, WI). Following
transformation into DH5 alpha, electrocompetent E. coli cells, a positive clone containing
an insert of the correct size was selected for sequence verification. DNA sequencing was
conducted using an ALF automated DNA sequencer (Amersham/Pharmacia Biotech).
Human SPARC oligonucleotide primers and sequence comparisons were based on
GenBank accession number NM 003118.

Generation of SPARC/MCF7 and JunD/MCF7 stable cell lines

SPARC/MCF7 and JunD/MCF7 stable cell lines were made utilizing the pLPCX
retroviral vector system (Clontech Corporation, Palo Alto, CA) according to
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manufacturer’s recommendations. Briefly, the human SPARC protein coding region was
subcloned from the pGEM7-Zf+ Hindlll/Clal site into the Hindlll/Clal site of pLPCX
retroviral vector (Clontech Corporation, Palo Alto, CA). The rat JunD protein coding
region (kind gift from Dr. Rodrigo Bravo, Bristol-Myers Squibb, Trenton, New Jersey)
was subcloned from Hindlll/Notl into a Hindlll/Notl digested LPCX vector. Purified
plasmid DNA containing the appropriate expression cassettes for SPARC and JunD were
transfected into the RetroPack™ PT67 packaging cell line in order to produce infectious
retrovirus. This cell line is derived from the murine fibroblast NIH3T3 cell line.
Retroviruses produced from these cells contain the dualtropic 10A1 viral envelope
protein thereby allowing for retroviral entry into target cells via the cell surface
receptor(s) RAMI (Pit2) and/or GALV (Pitl) (132, 133). PT67 cells were plated at a
density of 5 X 105cells/lOOmm plate. 24 hours later, cells were transfected with 12pg
DNA/lOOmm plate using FuGENE 6 reagent (Boehringer Mannheim) according to
manufacturer’s recommendations (DNA:FuGENE ratio= 2:1). After 48 hours PT67 cells
were placed under antibiotic selection using 2.5pg/ml of puromycin. Clonal populations
of antibiotic resistant cells were allowed to grow together until confluent. Growth media
containing virus was harvested and filtered through a 0.45 pm cellulose acetate filter for
subsequent infection of target cells. MCF7 cells were infected by incubating cells in the
presence of viral supernatant and lOpg/ml of polybrene. Cells were incubated with virus
for 6 hours then refed with Improved Minimal Essential Media with zinc option
(Mediatech Incorporated, Herndon, VA) containing 10% fetal bovine serum and 1%
penicillin/streptomycin. Forty-eight hours after infection, cells were placed under
antibiotic selection using 2.0pg/ml of puromycin. After approximately 3 weeks
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individual antibiotic resistant cell clones were isolated using sterile glass cloning rings
(8mm diameter X 6mm height). To accomplish this, tissue culture dishes containing cell
colonies were gently washed two times with 37°C phosphate buffered saline. Next, one
end of a cloning ring was coated with sterile petroleum jelly and placed over an
individual cell colony using sterilized forceps. A 50jul aliquot of trypsin/EDTA was
added to the inside of each cloning ring to facilitate removal of the cell colony and to
disperse cells. The trypsinized cells were then transferred to a single well of a 12-well
tissue culture dish using a pipette. Stable cell clones were maintained in Improved
Minimal Essential Medium with zinc option (Mediatech Incorporated, Herndon, VA)
containing 10% fetal bovine serum, 1% penicillin/streptomycin and 2.0pg/ml of
puromycin. Individual stable cell lines were then assayed SPARC or JunD protein
expression as described below.

Western blot analysis

Monolayer cultures of cells were washed twice using IX phosphate buffered
saline and collected in 1.5mls phosphate buffered saline for each 100mm plate. Cells
were then centrifuged at 16,000 X g at 4°C for 2 minutes. The resulting cell pellet was
resuspended in 0.25M Tris, pH 7.8 followed by a series of three freeze/thaw cycles to
facilitate cell lysis. The samples were then centrifuged at 16,000 X g at 4°C for 5
minutes. The supernatant was transferred to a new microfuge tube and protein was
quantitated using the Bradford method (134). 50-lOOpg of protein was mixed with
sample loading buffer (lOOmM Tris, pH 6.8, 2% sodium dodecylsulphate, 5% betamercaptoethanol, 15% glycerol and 0.025% bromophenol blue). Samples were denatured
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by heating for 3 minutes in a boiling water bath and then analyzed on a 10% sodium
dodecylsulfate-polyacrylamide gel electrophoresed in IX Tris/glycine running buffer.
Protein was transferred from the gel to a nitrocellulose membrane using a semi-dry
electroblot apparatus (200mA for 15 minutes then 360mA for 20 minutes).
Nitrocellulose membranes were washed twice in deionized water followed by a one
minute incubation in 100% isopropanol. Membranes were then blocked using 5% non
fat milk/lX Tris buffered saline for one hour at room temperature with constant rocking.
Next, samples were incubated for one hour at room temperature with a anti-SPARC
mouse monoclonal primary antibody (OST1 clone, Biodesign International, Saco, ME)
diluted 1:1,000 in 5% non-fat milk/lX Tris buffered saline. Membranes were washed
three times in IX Tris buffered saline/0.1% Tween-20 to remove unbound primary
antibody. Samples were subsequently incubated for one hour at room temperature with
anti-mouse horseradish peroxidase conjugated secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) diluted 1:5,000 in 5% non-fat milk/lX Tris buffered
saline. Protein was visualized by enhanced chemiluminescence (Amersham Biosciences,
Upsala, Sweden) and detected on film. Protein molecular weight was estimated using
Rainbow marker (Amersham Biosciences, Upsala, Sweden) or MagicMark™ (Invitrogen
Corporation, Carlsbad, CA) as protein mass standards.

Construction of antisense SPARC adenovirus

Replication incompetent adenoviruses were constructed using the Adeno-X™
Expression System (Clontech Corporation, Palo Alto, CA) according to manufacturer’s
recommendations. Briefly, the human SPARC coding region was subcloned from the
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Hindlll/Xhol sites of PGEM7-Zf+ and inserted into the Hindlll/Xhol sites of the plasmid
pcDNA3.1/Zeo (Invitrogen Corporation, Carlsbad, CA). pcDNA3.1/Zeo/SPARC was
subsequently digested with Aflll/Apal restriction enzymes to subclone the SPARC
coding region in the antisense orientation into a Aflll/Apal digested pShuttle vector
(Clontech Corporation, Palo Alto, CA). pShuttle/SPARC and pShuttle/LacZ plasmids
were digested with the restriction enzymes, I-Ceu-I and Pl-Scel and ligated into similarly
digested Adeno-X™ viral genomes resulting in adenovirus-SPARC antisense and
adenovirus-LacZ viral genomic DNA. Following digestion using Swal restriction
enzyme, adenovirus-SPARC antisense and adenovirus-LacZ plasmids were transformed
into DH5 alpha electrocompetent E. coli. Subsequently, adenoviral plasmid DNA was
purified using the NucleoBond® Plasmid Maxi Kit (Clontech Corporation, Palo Alto,
CA) according to manufacturer’s instructions. Purified plasmid DNA was digested with
Pacl restriction enzyme prior to transfection into the HEK293 packaging cell line.
HEK293 cells were seeded at a density of 3 X 106 cells/ 100mm tissue culture dish 24
hours prior to transfection. Cell were grown in a humidified chamber at 37°C and 5%
carbon dioxide in Dulbecco’s Modification of Eagle’s Medium with 10% fetal bovine
serum and 1% penicillin/streptomycin 24 hours prior to transfection. Cells were
transfected with purified plasmid DNA using FuGENE 6 reagent (Roche Diagnostics,
Indianapolis, IN) according to manufacturers recommendations (2:1 FuGENE
volume:DNA mass). Cells were harvested 7-14 days post-transfection when cytopathic
effect (CPE) was evident throughout the plate. The cells were then pelleted by
centrifugation and resuspended in phosphate buffered saline. Virus was freed from cells
by freezing and thawing cell pellets three times with vortexing after each thaw. This
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supernatant containing vims was used to re-infect HEK293 cells in order to increase the
viral titer. For infection, cells were seeded at a density of 1 X 106 cells/35mm tissue
culture dish. Twenty-four hours later, cell growth medium was removed and 1.0ml of
vims suspended in Dulbecco’s phosphate buffered saline (with calcium) was added to
each 35mm dish. Infections were conducted for 4 hours in a humidified chamber at 37°C
and 5% carbon dioxide. Following the 4 hour incubation, complete growth medium was
added and cells were refed with fresh medium the next day.
Following a single round of viral amplification, viral titer was determined using
the Adeno-X™ Rapid Titer Kit (Clontech Corporation, Palo Alto, CA) following
manufacturer’s instructions. Briefly, infected HEK293 cells were fixed in methanol and
rinsed two times with IX phosphate buffered saline. Samples were then incubated with
an anti-hexon, adenovirus specific, primary antibody. The primary antibody was then
washed away and a horse radish peroxidase conjugated secondary antibody was added.
Diaminobenzidine was added to the reaction to facilitate colorimetric detection.
Individual cells producing vims were readily detectable using conventional light
microscopy.
The amount of infectious viral particles following a single round of amplification
was typically 1-5 X 108 plaque forming units (pfu)/ml (see Appendix A, Fig. 40). In
order to determine the optimal multiplicity of infection (MOI) for c-Jun/MCF7 cells, a
series of infections were conducted over a broad range of MOI using adenovirus-LacZ as
a means of determining the number of infected cells (see Appendix A, Fig. 41).
Adenovirus-LacZ infected c-Jun/MCF7 cells were stained using the beta-galactosidase
staining kit (Invitrogen Corporation, Carlsbad, CA) according to manufacturer’s
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instructions. An optimal MOI of between 5-10 was determined to infect the majority of
cells without being cytotoxic. This MOI was used to infect c-Jun/MCF7 cells with
antisense SPARC adenovirus in order to suppress endogenous SPARC expression. A
time course following infection was conducted in order to determine the optimal time
following infection in which endogenous SPARC expression was suppressed to the
greatest extent. These conditions were used for all subsequent experiments.

In vitro cell motility and invasion assays

For invasion assays, a solution of collagen type IV was made in 0.01M acetic acid
in order to coat modified Boyden chamber membranes. Membranes were soaked
overnight at 4°C followed by coating with Matrigel™ (BD Biosciences, Franklin Lakes,
NJ). Cells were suspended in serum-free Improved Minimal Essential Media with zinc
option supplemented with 0.1% bovine serum albumin. NIH3T3 cell culture supernatant
was used as the chemoattractant added to the lower wells of a modified Boyden chamber
apparatus. Cells were incubated for 4-5 hours followed by staining with Diff-Quick®
(American Scientific Products, Chicago, IL) according to manufacturer’s instructions.
The number of cells that had migrated in response to the chemoattractant was determined
by counting cells from three fields of view at 40X magnification. Motility assays were
conducted using the same procedure except membranes were only coated with gelatin.

Cell proliferation assays

The rate of cell proliferation was determined using the CellTiter 96 NonRadioactive Cell Proliferation Assay Kit (Promega Corporation, Madison, WI) according
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to manufacturer’s instructions. This kit is a colorimetric assay based on the conversion of
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl) tetrasodium bromide to formazan via
the succinate-tetrazolium reductase system in viable cells (135). Cells were seeded at a
density of 5,000 cells/well in a 96-well plate and serum starved for 24 hours prior to
beginning the assay. The medium was then replaced with Improved Minimal Essential
Medium with zinc option containing 10% fetal bovine serum and 1%
penicillin/streptomycin. Four replicate plates were set up so that cell proliferation rates
could be measured at 24, 48, 72 and 96 hours. Each cell line/condition was assayed in
seven replicate wells for each time point. In addition, wells containing only media were
set up in order to serve as background controls. At the indicated time points, 15 pi of
MTT assay dye was added to each well followed by a 4 hour incubation at 37°C and 5%
carbon dioxide. Next, lOOpl of stop solution was added for solublization of the formazan
reaction product. Samples were subsequently incubated for 1 hour then mixed by
pipetting up and down. Bubbles were removed by aspiration and the sample absorbance
was recorded at 570nm using a micro titer plate reader. Each experiment was conducted
in triplicate. Mean absorbance values and standard deviation were calculated for each
cell line and time point. Linear regression analysis was conducted in order to determine
proliferation rates. The proliferation rate of empty vector control/MCF7 cells was set at
100% and the values of c-Jun/MCF7 and SPARC/MCF7 cells were expressed as percent
of empty vector control/MCF7 cells.
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Generation of c-Jun/MCF7 stable cell lines expressing SPARC siRNAs

The pSilencer 3.1-Hl-hygromycin plasmid based system (Ambion Incorporated,
Austin, TX) was used for expression of siRNA sequences designed against the human
SPARC mRNA. Four siRNA sequences were designed using guidelines available at
www.ambion.com. Briefly, the human SPARC mRNA sequence was analyzed for
adenine-adenine dinucleotide repeats. The 19 nucleotides immediately 5’ of adenineadenine repeats were recorded. Sequences that were 50-60% guanine and cytosine (G/C)
residues, without runs of three or more consecutive G/Cs, were given priority scores. Of
the sequences meeting these criteria, four sequences were selected that were predicted to
target different regions of the SPARC mRNA. Oligonucleotides were commercially
synthesized with 5’ phosphate modification and polyacrylamide gel purified (Integrated
DNA Technologies Incorporated, Coralville, IA). Lyophilized oligonucleotides were
resuspended at a concentration of 1pg/pl in nuclease-free water. 2jng of paired sense and
antisense oligonucleotides were mixed in 46jul of oligonucleotide annealing buffer
(Ambion Incorporated, Austin, TX) to facilitate complementary base pairing and
formation of duplex DNA. Annealing of oligonucleotides was accomplished by heating
to 90°C for 3 minutes followed by cooling in a heat block to 37°C. The duplexes were
then diluted 1:10 in nuclease-free water and 1jul was used in a ligation reaction. The
oligonucleotides were designed to have BamHI/Hindlll overhangs after annealing to
facilitate ligation into a BamHI/Hindlll digested pSilencer 3.1-Hl-hygromycin plasmid.
The following oligonucleotides were used:
SPARC+161 (sense):
5 ’ phos-gatcccgtttgatgatggtgcagaggttcaagagacctctgcaccatcatcaaattttttggaaa 3 ’
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SPARC +161 (antisense):
5 ’ phos-agcttttccaaaaaatttgatgatggtgcagaggtctcttgaacctctgcaccatcatcaaacgg 3 ’
SPARC +328 (sense):
5 ’ phos-gatcccggtgtgcagcaatgacaacttcaagagagttgtcattgctgcacaccttttttggaaa 3 ’
SPARC +328 (antisense):
5 ’ phos-agcttttccaaaaaaggtgtgcagcaatgacaactctcttgaagttgtcattgctgcacaccgg 3 ’
SPARC+418 (sense):
5 ’ phos-gatcccgctccacctggactacatcttcaagagagatgtagtccaggtggagcttttttggaaa 3 ’
SPARC +418 (antisense):
5 ’ phos-agcttttccaaaaaagctccacctggactacatctctcttgaagatgtagtccaggtggacggg 3 ’
SPARC +604 (sense):
5 ’ phos-gatcccgtgagaagcgcctggaggcattcaagagatgcctccaggcgcttctcattttttggaaa 3 ’
SPARC +604 (antisense):
5 ’ phos-agcttttccaaaaaatgagaagcgcctggaggcatctcttgaatgcctccaggcgcttctcacgg 3 ’
To generate stable cell lines expressing the individual siRNA transcripts,
c-Jun/MCF7 cells were plated at a density of 2.5 X 106 cells/lOOmm plate and grown in
Improved Minimal Essential Medium with zinc option, 10% fetal bovine serum and 1%
penicillin/streptomycin. Cells were transfected 24 hours later using 27pg of individual
SPARC siRNA/pSilencer 3.1-Hl-hygromycin expression plasmids. FuGENE 6
transfection reagent (Roche Diagnostics, East Rutherfod, NJ) was used to deliver plasmid
DNA (FuGENE:DNA ratio = 2:1). Twenty-four hours after transfection, cells were refed
with fresh, complete media containing 200pg/ml hygromycin (Clontech Corporation,
Palo Alto, CA) in order to select stable cell populations. Cell cultures were subsequently
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refed every other day with fresh media containing hygromycin. After approximately
three weeks, cell populations from the same plate (expressing the same individual
siRNA) were trypsinized, pooled and maintained as a single culture. SPARC protein
expression was determined by Western blot analysis as previously described in this
section. Expression of c-Jun protein was determined by Western blot analysis using a
rabbit polyclonal c-Jun specific antibody, c-Jun/AP-1 (Ab-1) (Oncogene Science,
Cambridge, MA) at a 1:5,000 dilution.

SPARC promoter/luciferase reporter plasmids

The SPARC promoter constructs corresponding to nucleotides -1409/+28
and-120/+28 in pGL2-Basic (Promega Corporation, Madison, WI) were a kind gift from
Dr. Marc Castellazzi and have been described elsewhere (129). To generate the SPARC
promoter 5’ deletion construct corresponding to positions -70/+28 we used polymerase
chain reaction to amplify this region from the SPARC promoter -1409/+28-pGL2-Basic
parental plasmid. The following primers were used: primer 1= -70/+28 5’
acggggtggaggggagatgacccag 3’, primer 2= pGL2-Basic primer 5’ ctttatgtttttggcgtcttcca
3’. 2ng of plasmid DNA was used as a template and mixed with the following PCR
master mix components: 4pl dNTPs (2.5mM each), 10X Advantage™ 2 reaction buffer
(Clontech Corporation), 150ng of each primer, 0.5pl Advantage2-HF enzyme mix
containing Taq polymerase and a proofreading enzyme (Clontech Corporation, Palo Alto,
CA). Themocycling conditions were as follows: step 1, 95°C for 2 minutes, step 2, 95°C
for 30 seconds, step 3, 65°C for 30 seconds, step 4, 68°C for 30 seconds, repeat steps 2-4
for a total of 25 cycles. PCR products were analyzed on a 1% low melt agarose gel and
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visualized by staining with ethidium bromide and gel purified using the Qiaquick Gel
Extraction Kit (Qiagen Corporation, Valencia, CA). Two-step PCR was used to generate
point mutations within the SPARC promoter AP-1 like site at -1051/-1045. The pGL2Basic forward primer 5’ tgtatcttatggtactgtaactg 3’, designated A l, corresponds to a region
of the pGL2-Basic plasmid which is upstream of the plasmid Smal site. The pGL2-Basic
reverse primer 5’ ctttatgtttttggcgtcttcca 3’, designated B l, corresponds to a region
immediately downstream of the plasmid Hindlll site. The internal primers used to
introduce point mutations to the —1051/-1045 AP-1 like site are as follows: -1051/-1045
mutated to consensus= primer (C l) 5’ gcctgggcgacagagtgagtcag 3’ and primer (D l) 5’
gttttgagacagagtctgactcactc 3’, -1051/-1045 more mutated= primer (El) 5’
gcctgggcgacagagcgaatgag 3’ and primer (FI) 5’ gttttgagacagagtctcattcgctc 3 ’.
PCR was performed using the following primer combinations: A l/D l, A l/F l,
B l/C l, B l/E l. The PCR master mix for each of these reactions contained the following
components: 4pl dNTPs (2.5mM each), 10X Advantage™ 2 reaction buffer (Clontech
Corporation, Palo Alto, CA), 150ng of each primer, 0.5 pi Advantage™ 2 enzyme mix
containing Taq polymerase and a proofreading enzyme (Clontech Corporation, Palo Alto,
CA). Themocycling conditions were as follows: step 1, 95°C for 2 minutes, step 2, 95°C
for 30 seconds, step 3, 63°C for 30 seconds, step 4, 68°C for 60 seconds, repeat steps 2-4
for a total of 25 cycles. Products were purified on a 1% low-melt agarose gel and gel
purified using the Qiaquick Gel Extraction Kit (Qiagen Corporation, Valencia, CA). A
portion of the purified PCR products containing the corresponding mutations were mixed
into a second PCR reaction to produce the full-length mutated product. PCR products
generated with the following primer combinations were mixed and used as the template
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for subsequent PCR reactions: A l/D l and B l/C l containing the mutation to a consensus
context, A l/F l and B l/E l containing the mutations to a more mutated context.
Amplification of full-length mutant promoter fragments was done using primers A1 and
B1 under the following thermocycling conditions: step 1, 95°C for 2 minutes, step 2,
95°C for 30 seconds, step 3, 63°C for 30 seconds, step 4, 68°C for 90 seconds, repeat
steps 2-4 for a total of 25 cycles. These full-length mutated PCR products were gel
purified using the Qiaquick Gel Extraction Kit (Qiagen Corporation, Valencia, CA)
according to manufacturer’s instructions. Purified PCR amplicons were treated with
DNA polymerase I large (Klenow) fragment followed by digestion with Hindlll
restriction enzyme. The mutant promoter fragments were subsequently cloned into a
Smal/Hindlll digested pGL2-Basic vector. Mutations were confirmed by DNA
sequencing.

Luciferase assays

Cells were seeded in 6-well tissue culture plates (area=35mm /well) at a density
of 3 x 105 cells/well approximately 24 hours prior to transfection. 3pg of the indicated
plasmid DNA was added to 6pl of FuGENE 6 (Roche Diagnostics, East Rutherfod, NJ)
reagent pre-mixed with serum-free Improved Minimal Essential Media and added
dropwise to each well. After 48 hours, cells were washed twice with IX phosphate
buffered saline (PBS). Following the final PBS wash, 150pl of Reporter Lysis Buffer
(Promega Corporation, Madison, WI) was added to cells and incubated for 10 minutes.
These samples were frozen at -80°C for at least 1 hour to facilitate cell lysis and then
collected for analysis. Luciferase assays were done following manufacturers
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recommendations and quantitated using a luminometer (Turner Designs Incorporated,
Sunnyvale, CA) with the following parameters: delay= 2 seconds, integration= 15
seconds, replicates= 3. Relative luciferase values were normalized to protein
concentration per volume assayed (assay amounts were 20p1 unless the luciferase activity
was outside of the linear range of detection in which case protein samples were diluted
accordingly in IX lysis buffer). Protein quantitation was conducted using the Bradford
method (134).

Nuclear extract preparation

Nuclear extracts were prepared according to a modification of the procedure
established by Dignam (136). Monolayer cell cultures were washed two times with
phosphate buffered saline and collected in a buffer consisting of lOmM HEPES pH 7.9,
1.5mM magnesium chloride, lOmM potassium chloride, 0.5% NP-40, 2pg/ml aprotinin,
0.5pg/ml leupeptin, lpg/ml pepstatin, ImM PMSF, 0.5mM DTT. Cells were incubated
on ice for 10 minutes followed by centrifugation at 16,000 X g at 4°C. The nuclear pellet
was resuspended in 20mM HEPES pH 7.9, 25% glycerol, 0.42M sodium chloride,
1.5mM magnesium chloride, 0.2mM EDTA, 1pg/ml aprotinin, 0.5pg/ml leupeptin,
lpg/ml pepstatin, ImM PMSF, 0.5mM DTT. The pellet was incubated for 30 minutes on
ice with gentle mixing at 5 minute intervals. This mixture was then centrifuged at 16,000
X g for 30 minutes at 4°C. The supernatant was collected and dialyzed against a buffer
consisting of 20mM HEPES pH 7.9, 20% glycerol, 0.1M potassium chloride, 0.2mM
EDTA, ImM PMSF, 0.5mM DTT for 4 hours at 4°C. The dialysis buffer was changed
once during the 4 hour incubation. Samples were snap-frozen using a dry ice-ethanol
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bath and stored in 30 j l i 1 aliquots at -80°C. Protein concentration was determined using
the Bradford method (134).

Gel Shifts, antibody supershifts and competitions

Empty vector control/MCF7, c-Jun/MCF7 and JunD/MCF7 nuclear extracts were
prepared as previously described in this section.

32

P labeled gel shift probes were

prepared using partially overlapping, complementary oligonucleotide primers as
indicated. Oligonucleotide primer pairs were annealed by heating to 90° C for 3 minutes
followed by cooling to room temperature on the bench top. DNA polymerase I large
32

(Klenow) fragment was used to fill-in single stranded regions with alpha- P dNTP
(alpha-32P dATP or alpha-32P dTTP depending on probe) and non-radiolabeled dNTPs.
Radiolabeled gel shift probes were subsequently extracted once with an equal volume of
phenol and purified from unincorporated radiolabel using a Chromaspin-10 TE
chromatography column (Clontech Corporation, Palo Alto, CA). The specific activity of
radiolabeled probes was quantitated using a liquid scintillation counter and expressed as
counts per minute (cpm) as indicated in individual figure legends. A 2X gel shift reaction
buffer for AP-1 binding consisted of 20mM HEPES, 35% glycerol, 0.2mM EDTA,
40mM sodium chloride, 8mM magnesium chloride, 5mM DTT (made fresh), 4mM
spermidine, Ipg poly-dldC and 0.1% NP-40. AP-1 DNA binding competitors were
generated in the same way as 32 P radiolabeled probes except a full complement of nonradiolabeled dNTPs were used in the labeling reaction. Cold competitors were added in
T9

the indicated amounts for 20 minutes prior to incubation with the appropriate P labeled
probe. Gel shifts using antibodies to either compete or supershift DNA bound proteins
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were done by pre-incubating the nuclear extracts for 20 minutes with 2pg of anti- c-Jun
antibody directed against the DNA binding domain (Santa Cruz Biotechnology, Santa
Cruz, CA), 2jig of anti Fra-1 antibody R-20 clone (Santa Cruz Biotechnology, Santa
Cruz, CA), 2pg of anti-Spl antibody PEP-1 (Santa Cruz Biotechnology, Santa Cruz,
CA), 2pg of anti-pl30 antibody N-17 (Santa Cruz Biotechnology, Santa Cruz, CA) or
2|ig of anti-pl6 antibody N-20 (Santa Cruz Biotechnology, Santa Cruz, CA). lpg polydldC was added to each reaction to inhibit non-specific protein/DNA interactions.
Reactions were analyzed on 6% non-denaturing polyacrylamide gels electrophoresed in
1% TBE running buffer at room temperature. Gels were pre-run for 20 minutes at 20mA
constant current with lOpil of 2X gel shift reaction buffer loaded in each well. Gel shift
reactions were then loaded onto the gel and electrophoresis was continued for
approximately 2 hours at 30mA constant current. Gels were then transferred to filter
paper and dried at 80°C for 2 hours followed by autoradiography for detection of
protein/DNA complexes.
To analyze DNA binding of protein complexes with Sp family binding specificity
the gel shift reactions were done as indicated above with the following modifications.
Reactions were electrophoresed on a 5% non-denaturing polyacrylamide gel in 0.5%
TBE running buffer at room temperature unless otherwise noted. Sp 1 consensus and
mutant competitors (kind gift from Dr. Julie Kerry, Eastern Virginia Medical School)
were added to nuclear extracts and DNA binding buffer 20 minutes prior to incubation
with the indicated probe. The binding buffer used was as follows: 20mM HEPES, 35%
glycerol, 0.2mM EDTA, 40mM sodium chloride, 8mM magnesium chloride, 5mM DTT
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(made fresh), 4mM spermidine, 1|ig poly-dldC/reaction and 0.1% NP-40. The following
gel shift probes were used in these studies:
PG32-1 consensus AP-1 probe:
Forward primer: 5’ acccggggatcctctagaatgactcatcgg 3’
Reverse primer: 5’ cttgcatgcctgcaggatccgatgagtcat 3’
SPARC promoter AP-1 like site at —1051/-1045 mutated to consensus:
Forward primer: 5’ gcctgggcgacagagtgagtcag 3’
Reverse primer: 5’ gttttgagacagagtctgactcactc 3 ’
SPARC promoter AP-1 like site at -1051/-1045 mutated to wild type:
Forward primer: 5’ gcctgggcgacagagtgagtgag 3’
Reverse primer: 5’ gttttgagacagagtctcactcactc 3’
SPARC promoter AP-1 like site at -1051/-1045 mutated to more mutated:
Forward primer: 5’ gcctgggcgacagagcgaatgag 3’
Reverse primer: 5’ gttttgagacagagtctcattcgctc 3 ’
Heterologous competitor for AP-1 gel shift reactions:
Forward primer: 5’ ttgacgtcaataatgacg 3’
Reverse primer: 5 ’ tatgggaacatacgtcat 3 ’
Spl consensus gel shift competitor probe:
Forward primer: 5’ tcatacaacgtagggcgggattgttgagaa 3’
Reverse primer: 5’ tgttctcaacaatcccgccctacgttgtat 3’
Spl mutant gel shift competitor probe:
Forward primer: 5’ tcatacaacgtagagtactattgttgagaa 3’
Reverse primer: 5 ’ tgttctcaacaatagtactctacgttgtat 3 ’
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SPARC promoter-120/-83 gel shift probe:
Forward primer: 5’ gggagaaggaggaggccgggggaag 3’
Reverse primer: 5 ’ ctcctgtctcctccttcccccgg 3 ’

RNA isolation

Total cellular RNA was isolated using TRIZOL® reagent (Invitrogen Corporation,
Carlsbad, CA) according to the manufacturers protocol. Cells were washed two times in
phosphate buffered saline followed by the addition of TRIZOL® reagent (2.5mls for
100mm plate, 1ml for 60mm plate). Samples were collected using a sterile plastic
scraper and aliquoted into nuclease-free microfuge tubes. Samples were then vortexed
for 15 seconds and incubated at room temperature for 5 minutes. Chloroform was then
added and samples were shaken by hand vigorously for 30 seconds followed by
incubation for 5 minutes at room temperature. Samples were subsequently centrifuged at
10,000 X g at 4°C for 10 minutes. Following centrifugation, the upper (aqueous) phase
was carefully aliquoted into a new nuclease-free microfuge tube using a nuclease-free,
aerosol barrier pipette tip. An equal volume of 100% isopropanol was then added and the
sample was vortexed briefly followed by a 10 minute incubation at room temperature.
The sample was then centrifuged at 10,000 X g for 15 minutes at 4°C to collect the RNA
precipitate. Following centrifugation, the supernatant was carefully removed from the
RNA pellet and discarded. Ice-cold 70% ethanol was gently added to the pellet followed
by a final centrifugation at 10,000 X g for 7 minutes. The ethanol was then removed and
the pellet was air dried. The RNA pellet was resuspended in an appropriate volume of
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nuclease-free water. An aliquot of the purified RNA was quantitated by
spectophotometry at 260nm.

Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR)

1OOng of total RNA was incubated in the presence of 20pmol of random
hexamers (Applied Biosystems, Foster City, CA) at 70°C for 2 minutes followed by snapcooling at 4°C. The reverse transcription master mix was then added to the RNA/primer
mixture. The reverse transcriptase master mix consisted of 5pi of a 5X Moloney Murine
Leukemia Virus reverse transcriptase (MMLV-RT) reaction buffer (Promega
Corporation, Madison, WI), 20 units of recombinant Rnasin (Promega Corporation,
Madison, WI), 4pl of dNTP mix (2.5mM each), 200 units of Moloney Murine Leukemia
Virus reverse transcriptase (Promega Corporation, Madison, WI) and nuclease-free water
(Promega Corporation, Madison, WI). The reverse transcription reaction was then
incubated at 42°C for 1 hour followed by heating at 94°C for 5 minutes to halt cDNA
synthesis. The samples were then cooled to 4°C until further use.
A 1.5pl aliquot of the reverse transcription reaction was used to amplify a portion
of the 18S ribosomal subunit gene transcript using the following oligonucleotide primers:
18S sense primer= 5’ tgactctagataacctcggg 3’, 18S antisense primer= 5’
cccaagatccaactacgagc 3’. The PCR reaction mixture consisted of the following: 1.5pl of
template cDNA, 5pi of 10X PCR buffer (Clontech Corporation, Palo Alto, CA), 4pl
dNTP mix (2.5mM each), 150ng of sense and antisense 18S primers, 0.5pl of Titanium™
Taq DNA polymerase (Clontech Corporation, Palo Alto, CA) and nuclease-free water for
a 50pl total reaction volume. Polymerase chain reaction for 18S was conducted using a
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Biometra T-Gradient Thermocycler as follows: step one, 95°C for 1 minute, step two,
95°C for 30 seconds, step three, 55°C for 30 seconds, step four, 68°C for 45 seconds.
Steps 2-4 were repeated for a total of 13 cycles which corresponded to mid-log phase
amplification using 1OOng of input, total cellular RNA. The expected amplification
product is 403 base pairs. The method for determining the mid-log phase of
amplification is described later in this section.
A 2 pi aliquot of the reverse transcription reaction was used to amplify a portion
of SPARC utilizing a gene specific primer pair that would span intron regions. The
primers used for SPARC RT-PCR were as follows: SPARC sense primer= 5’
gtcagaagcttatgagggcctggatcttctttctcc 3’, SPARC antisense primer= 5’
gtcagatcgattggatttagatcacaagatccttgtcg 3’. The PCR reaction mixture consisted of the
following: 2pl of template cDNA, 5pl of 10X PCR buffer (Clontech Corporation, Palo
Alto, CA), 4pl dNTP mix (2.5mM each), 150ng of sense and antisense SPARC primers,
0.5pl of Titanium™ Taq DNA polymerase (Clontech Corporation, Palo Alto, CA) and
nuclease-free water for a 50pl total reaction volume. Polymerase chain reaction for
SPARC was conducted using a Biometra T-Gradient Thermocycler as follows: step one,
95°C for 1 minute, step two, 95°C for 30 seconds, step 3, 68°C for 30 seconds, step 4,
68°C for 1 minute. Steps 2-4 were repeated for a total of 30 cycles which corresponded
to mid-log phase amplification using lOOng of input, total cellular RNA. The expected
amplicon size is 944 base pairs. The method for determining the mid-log phase of
amplification is described later in this section.
For visualization of RT-PCR amplicons, reaction products were electrophoresed
on a 1.5% agarose gel stained with GelStar® reagent (Cambrex Corporation, East
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Rutherford, NJ). Following ultraviolet transillumination at 312nm, images were captured
using a Kodak DC40 digital camera equipped with an ethidium bromide lens filter and
PCR amplicon signals quantitated using Kodak ID Image Analysis software package.
In order to utilize 18S as an endogenous control for standardization purposes it
was necessary to identify when 18S amplification was in mid-log phase to allow for
appropriate quantitation. This was done by conducting multiple, parallel 18S PCR
reactions over a range of cycle numbers and input RNA concentrations utilizing aliquots
from the same cDNA mixtures as the template. For SPARC (and other indicated genes),
mid-log phase amplification was conducted by testing samples over a range of different
cycle numbers and varying input RNA concentration as well. Following quantitation
using Kodak ID Image Analysis software (Kodak Corporation), the values were plotted
as relative intensity vs. cycle number as well as relative intensity vs. input RNA amount.
The cycle number which correlated to mid-log phase amplification using lOOng of input
total RNA was used for all subsequent experiments for standardization of SPARC
expression between the two cell types. Input RNA was adjusted to ten-fold higher
(l.Opg) and ten-fold lower (lOng) in the reverse transcription reaction to ensure linear
amplification over a one-log change in RNA concentration in either direction.
The primers used for RT-PCR analysis of AP-1 family gene expression were as
follows:
fra-1 sense= (position 410-427, GenBank accession number X16707)=
5’ AGGAAGGAACTGACCGAC 3’
fra-1 antisense= (position 889-906, GenBank accession number X16707)=
5’ GAAGGGGAGGAGACATTG 3’
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fosB sense= (position 3137-3155, GenBank accession number NM_006732)=
5’ GCTATTTATCCCTTTCCTG 3’
fosB antisense= (position 3579-3597, GenBank accession number NM_006732)=
5’ TGCTCACACTCTCACACTC 3’
c-jun sense= (position 2036-2065, GenBank accession number J04111)=
5’ GCATGAGGAACCGCATCGCTGCCTCCAAGT 3’
c-jun antisense= (position 2416-2445, GenBank accession number J04111)=
5’ GCGACCAAGTCC TTCCCACTCGTGCACACT 3’
junB sense= (position 1469-1496, GenBank accession number NM_002229)=
5’ CCAGTCCTTCCACCTCGACGTTTACAAG 3’
junB antisense= (position 1696-1725, GenBank accession number NM_002229)=
5’ GACTAAGTGCGTGTTTCTTTTTCCACAGTAC 3’
junD sense= (position 1273-1293, GenBank accession number X51346)=
5’ CAGCCTCAAACCCTGCCTTTC 3’
junD antisense= (position 1571-1590, GenBank accession number X51346)=
5’ AACAGAAAACCGGGCGAACC 3 ’
c-fos sense= (position 1170-1187, GenBank accession number NM_005252.2)=
5’ TCTTCCTTCGTCTTCACC 3’
c-fos antisense= (position 1727-1746, GenBank accession number NM_005252.2)
5’ AAT CAGAAC AC ACT ATT GCC 3 ’
fra-2 sense= (position 570-587, GenBank accession number BC022791)=
5’ AGGAGGAGAGATGAGCAG 3’
fra-2 antisense= (position 1070-1087, GenBank accession number BC022791)=
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5’ GG AT AGGTGAAGACGAGG 3’
Conditions used for semi-quantitative RT-PCR analysis of AP-1 family members
were the same as for SPARC except that a 66°C annealing temperature was used for each
primer pair during PCR. Mid-log phase amplification conditions were determined for
each AP-1 family member using the same technique described previously in this section
for SPARC and 18S. The number of PCR amplification cycles required for mid-log
phase amplification using lOOng of total RNA as input for reverse transcription were as
follows: fra-l= 29 cycles, fosB= 36 cycles, c-jun= 30 cycles, junB= 34 cycles, junD= 32
cycles, c-fos= 36 cycles, fra-2= 30 cycles.

Chromatin immunoprecipitation (ChIP) analysis

Cells were seeded in duplicate 150mm tissue culture plates at a density of 3 X 106
cells per plate. Approximately 48 hours later, cells from one plate were counted in order
to normalize for differences in cell number. To the second plate, a 37% stock of
formaldehyde was added directly to the tissue culture medium to achieve a final
concentration of 1%. The plate was gently rocked to facilitate mixing and then the plates
were incubated at 37°C for 10 minutes. The tissue culture media was removed and the
cells were washed 3 times in ice-cold phosphate buffered saline plus protease inhibitors
(aprotinin lpg/ml, leupeptin lpg/ml, PMSF ImM final concentration). For ChIP analysis
of acetylated histones, the histone deacetylase inhibitor, trichostatin A, was added to
wash buffers at a final concentration of lOOng/ml. Cells were collected by gentle
scraping using a rubber policeman. The cell suspension was centrifuged at 1,500 X g for
5 minutes at 4°C in order to pellet cells. The supernatant was discarded and the cell pellet

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

42
was resuspended in 200pl of cell lysis buffer (1% SDS, lOmM EDTA, 50mM Tris-HCl,
pH 8.1, aprotinin lpg/ml, leupeptin lpg/ml, PMSF ImM) for every 1 X 106 cells
(estimated by cell counts). Samples were then incubated at room temperature for 10
minutes to allow for membrane dissociation. An aliquot equal to 8 X 106 cells was
subjected to sonication. A Fisherbrand 60 watt sonic dismembrator with a 1/8” diameter
tip was used for all sonication (Fisher Scientific Corporation, Pittsburgh, PA). Sonication
consisted of eight, 6 watt pulses, each lasting 12 seconds. Samples were kept on ice
during the entire sonication procedure and a 1 minute incubation on ice was done in
between each pulse to prevent sample heating. Under these conditions, DNA was
sheared to an average size of 500-1,000 base pairs. Following sonication, samples were
centrifuged for at 10,000 X g for 5 minutes at 4°C. The supernatant, containing soluble
chromatin, was collected and distributed into 200pl aliquots for each
immunoprecipitation. A lOOpl aliquot was saved and designated as input chromatin not
subjected to immunoprecipitation. This sample was saved until the crosslink reversal
step. Chromatin aliquots subjected to immunoprecipitation were diluted in 1700pl of icecold ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM TrisHCl, pH 8.1, 167mM sodium chloride, lpg/ml aprotinin, lpg/ml leupeptin, ImM PMSF).
Samples were then pre-cleared using 80pl of salmon sperm DNA/protein A agarose
(stock= 1.5ml packed beads with 600pg sonicated salmon sperm DNA, 500pg BSA
1.5mg recombinant protein A, 50% slurry up to 3mls suspended in TE with 0.05%
sodium azide). For pre-clearing, samples were incubated at 4°C for 1 hour with constant
rotation. Next, samples were centrifuged for 1 minute at 100 X g in a tabletop microfuge
in order to pellet beads. Supernatants were aliquoted into new, nuclease-ffee microfuge
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tubes followed by the addition of lOjug of antibody. The following antibodies were used
in chromatin immunoprecipitation analysis: anti-tetraacetylated (K5, K8, K12, K16)
histone H4 (Upstate Biotechnology, Charlottesville, VA) catalog #06-866, antidiacetylated (K9, K14) histone H3 (Upstate Biotechnology, Charlottesville, VA) catalog
#06-599, anti-dimethyl histone H3 lysine 4 (Upstate Biotechnology, Charlottesville, VA)
catalog #07-030, anti-trimethyl histone H3 lysine 9 (Abeam Ltd., Cambridge, United
Kingdom) catalog #ab8898, anti-Fra-1 R-20 clone (Santa Cruz Biotechnology, Santa
Cruz, CA) catalog #sc-605, anti-c-Jun H79 clone (Santa Cruz Biotechnology, Santa Cruz,
CA) catalog #sc-1694, anti-Neu C-18 clone catalog #sc-284 (Santa Cruz Biotechnology,
Santa Cruz, CA), anti-Spl PEP 2 clone (Santa Cruz Biotechnology, Santa Cruz, CA)
catalog #sc-59.
Samples were immunoprecipitated overnight at 4°C with constant rotation. The
next day, antibody/protein/DNA complexes were isolated by adding 60pl of protein A
agarose/sheared salmon sperm DNA to the samples followed by incubation for 2 hours at
4°C with constant rotation. Samples were then centrifuged at 100 X g for 1 minute in a
tabletop microfuge. The supernatant was discarded and then the samples washed one
time for 5 minutes at 4°C with constant rotation using 1ml of ice-cold low salt wash
buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 150mM
sodium chloride). Samples were then centrifuged at 100 X g for 1 minute in a tabletop
microfuge to collect complexes. Supernatants were discarded and samples were
subjected to a second wash for 5 minutes at 4°C with constant rotation using 1ml of icecold high salt wash buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM Tris-HCl,
pH 8.1, 500mM sodium chloride). Samples were then centrifuged at 100 X g for 1
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minute in a tabletop microfuge to collect complexes. Supernatants were discarded and
samples washed a third time for 5 minutes at 4°C with constant rotation using 1ml of icecold lithium chloride wash buffer (0.25M lithium chloride, 1% NP-40, 1% sodium
deoxycholate, ImM EDTA, lOmM Tris-HCl, pH 8.1). Samples were then centrifuged at
100 X g for 1 minute in a tabletop microfuge to collect complexes. Supernatants were
discarded and samples washed a fourth time for 5 minutes at 4°C with constant rotation
using 1ml of ice-cold Tris/EDTA buffer (lOmM Tris-HCl, ImM EDTA, pH 8.0).
Samples were centrifuged at 100 X g for 1 minute in a tabletop microfuge to collect
complexes and washed a final time using 1ml of ice-cold Tris/EDTA buffer. Following
this final wash, immunoprecipitated protein/DNA complexes were eluted off of the
protein A agarose beads by vortexing samples with 250jul of 1% sodium
dodecylsulfate/O.lM sodium bicarbonate followed by a 15 minute incubation at room
temperature with constant rotation. Samples were centrifuged at 100 X g in a tabletop
microfuge and the supernatant transferred into a new nuclease-free tube. The elution
process was repeated a second time and eluted supernatants (5 00 pi) combined. Input
chromatin samples were thawed and diluted by adding 400pl of nuclease-free water. In
order to reverse protein/DNA crosslinks, all samples received 20pl of 5M sodium
chloride followed by incubation for at least 4 hours at 65°C. DNA was subsequently
purified by extracting samples with an equal volume of phenol and then an equal volume
of chloroform. DNA was precipitated by adding 2.5 volumes of ice-cold 100% ethanol
and 20pg of glycogen. Samples were incubated for at least 5 hours at -20°C. Samples
were then centrifuged at 16,000 X g for 30 minutes at 4°C in order to pellet DNA. Pellets
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were washed once with 70% ethanol then air-dried. DNA was resuspended in 50pl of
nuclease-free water for subsequent PCR analysis.
Chromatin immunoprecipitation PCR analysis of the SPARC proximal promoter
region was conducted using the following two oligonucleotide primers: primer 1=5'
cagccctggcactctgtgagtcggt 3' corresponding to nucleotide position -257/-233 of the
human SPARC promoter and primer 2= 5' ggcagtctgaaggaccgcgggaatggagg 3',
corresponding to nucleotide position +211A of the human SPARC promoter. PCR
reactions consisted of 5 pi of 10X Titanium™ Taq buffer (Clontech Corporation, Palo
Alto, CA), 4pl of a dNTP mix (2.5mM each dATP, dTTP, dCTP, dGTP), 200ng each of
primer 1 and primer 2, 0.5pl of Titanium™ Taq DNA polymerase (Clontech Corporation,
Palo Alto, CA), and nuclease-free water in a reaction volume of 48pl. 2pl of
immunoprecipitated DNA was added as the template for ChIP PCR. In addition, several
dilutions of input DNA (non-immunoprecipitated sample) were analyzed by PCR under
the same conditions in order to demonstrate that the reactions were conducted under non
saturating, semi-quantitative conditions. PCR was conducted using a Biometra TGradient Thermocycler as follows: step 1, 95°C for 3 minutes, step 2, 95°C for 1 minute,
step 3, 68°C for 45 seconds, step 4, 68°C for 45 seconds. Steps 2-4 were repeated an
additional 29-35 times depending on empirical determination of optimal cycle number for
each sample so that reactions were analyzed within the linear range of PCR amplification.
Reactions were subsequently cooled to 4°C and 15 pi of each reaction was analyzed by
agarose gel electrophoresis. 0.8% agarose gels in IX TBE were prepared and stained
with IX GelStar® reagent (Cambrex Corporation, East Rutherford, NJ) in order to
visualize PCR amplification products by ultraviolet transillumination at 3 12nm. Gel
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images were captured using a Kodak DC40 digital camera equipped with an ethidium
bromide filter. Images were analyzed by densitometry using Kodak ID Digital Science
imaging software in order to quantitate PCR amplicon signal intensities. For
quantitation, pixel intensity values for individual immunoprecipitated samples signal
intensity compared with input DNA signal on the same gel from the same batch of
chromatin preparation. This was represented as fold enrichment relative to input DNA
signal. Comparisons between cell lines were done by calculating differences in fold
enrichment for each antibody. At least two independent chromatin preparations were
analyzed for each immunoprecipitation.

In vitro methylation of plasmid DNA

Twenty units of recombinant Hpall methylase (New England Biolabs, Ipswich,
MA) were used to methylate 1Opg of SPARC promoter/pGL2-Basic luciferase reporter
plasmid DNA in a reaction containing IX Hpall methylase reaction buffer (New England
Biolabs, Ipswich, MA), 80pM S-adenosyl methionine (New England Biolabs, Ipswich,
MA) and nuclease-free water in a total reaction volume of 100 pi. Samples were
incubated at 37°C for 16 hours. After 4 hours, reactions were supplemented with fresh Sadenosyl methionine. The enzyme was then heat inactivated by incubating samples at
70°C for 10 minutes. DNA was then purified using Qiaquick Gel Extraction Kit (Qiagen
Corporation, Valencia, CA) according to manufacturers instructions and eluted in
nuclease-free water. Two, 500ng aliquots (estimated from input) of purified Hpall
methylated DNA were subsequently digested using Hpall or MspI restriction enzymes to
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determine the completeness of in vitro methylation. Two independent Hpall methylated
plasmid preparations were tested.

In vitro methylation of gel shift probes

A gel shift probe spanning the region from -120/-83 of the human SPARC
promoter was synthesized as described elsewhere in this section. Following probe
quantitation, an equal amount of probe (as determined by liquid scintillation counting)
was subjected to in vitro methylation using recombinant Hpall methylase (New England
Biolabs, Ipswich, MA). A second aliquot of the probe was “mock” methylated in a
reaction lacking Hpall methylase. Following methylation reactions, gel shift probes were
phenol extracted once and purified using a Chromaspin-10 TE chromatography column
(Clontech Corporation, Palo Alto, CA). Samples were re-quantitated by scintillation
counting to determine cpm/pl of purified probe. Equal aliquots (25,000cpm/reaction) of
mock and Hpall methylated gel shift probes were digested with 20 units of Hpall or MspI
restriction enzymes in order to determine the efficiency of in vitro probe methylation.
'I'j
The P labeled gel shift probes from these restriction enzyme digestion reactions were
extracted once with an equal volume of phenol and purified using a Chromaspin-10 TE
chromatography column (Clontech Corporation, Palo Alto, CA). Digested mock
methylated and Hpall methylated probes were resolved on a non-denaturing
polyacrylamide gel as described previously in this Chapter. The completeness of
methylation was determined by comparing the molecular weight of the mock methylated
probe and Hpall methylated probe digested with Hpall restriction enzyme. At least two
independent preparations of Hpall methylated gel shift probes were assayed.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

48
H pall/M spI mapping of SPARC promoter methylation

Purified genomic DNA was separated into three separate 1pg aliquots. One
aliquot was incubated with restriction enzyme digestion reaction mix without enzyme
(designated as uncut). A second aliquot was digested with the restriction enzyme Hpall.
A third aliquot was digested with the restriction enzyme Mspl. Samples were digested at
37°C for 4 hours. Samples were then incubated for 10 minutes at 70°C to heat inactivate
the enzymes. Reactions were diluted to lOng/pl in nuclease-free water. A 2.5jul aliquot
from each reaction was subjected to PCR using the following primer pairs:
SPARC promoter Hpall/MspI site #1:
Forward primer: 5’ gaagccaaggcattcggattgcccaag 3’
Reverse primer: 5’ gttttgagacagagtctcactcactc 3 ’
SPARC promoter Hpall/MspI site #2:
Forward primer: 5 ’ gcctgggcgacagagtgagtga 3 ’
Reverse primer: 5 ’ ggctgctgcctaaaccgactcac 3 ’
SPARC promoter Hpall/MspI site #3:
Forward primer: 5’ catatataacaggagtgacccaag 3’
Reverse primer: 5 ’ gctgtcctgaccaaacgtcccaacc 3 ’
SPARC promoter Hpall/MspI site #4:
Forward primer: 5’ ggttgggacgtttggtcaggacagc 3’
Reverse primer: 5 ’ gggcgtctgaaggaccgcgggaatgtggagg 3 ’
Primers were designed to flank individual Hpall/MspI restriction enzyme
digestion sites. Polymerase chain reaction for SPARC was conducted using a Biometra
T-Gradient thermocycler as follows: step one, 95°C for 3 minutes, step two, 95°C for 45
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seconds, step 3, 68°C for 30 seconds, step 4, 68°C for 1 minute. Steps 2-4 were repeated
for a total of 30 cycles. PCR reaction products were separated by agarose gel
electrophoresis and visualized by GelStar® nucleic acid stain (Cambrex Corporation, East
Rutherford, NJ) via ultraviolet transilluminatation at 3 12nm. A PCR reaction in which
template was omitted was run with each sample set as a negative control. The expected
PCR amplicon sizes for SPARC promoter Hpall/MspI site #1= 252 base pairs, SPARC
promoter Hpall/MspI site #2= 847 base pairs, SPARC promoter Hpall/MspI site #3= 711
base pairs, SPARC promoter Hpall/MspI site #4= 180 base pairs.

5-aza-2’deoxycytidine and trichostatin A treatment of cells

A 5mM stock of 5-aza-2’deoxycytidine (Sigma-Aldrich Corporation, St. Louis,
MO) was made fresh daily in sterile water and then filter sterilized using a 0.22pm
syringe filter. Cells received fresh drug once daily for the indicated times and
concentrations. A trichostatin A (Wako Chemicals USA, Incorporated, Richmond, VA)
stock solution was prepared in 100% ethanol and stored at -20°C. When used in
combination with 5-aza-2’deoxycytidine, trichostatin A was added at the end of the time
course (the last 12-14 hours) at a final concentration of lOOng/ml. When trichostatin A
was used alone, cells were incubated for 60 hours before the drug was added. As a
negative control for trichostatin A experiments, parallel samples were treated with the
same volume of 100% ethanol vehicle.
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Genomic DNA isolation

Genomic DNA was isolated from MCF7 vector control cells and c-Jun/MCF7
cells using a Qiagen Genomic DNA Isolation Kit (Qiagen Corporation, Valencia, CA).
Cells were seeded at a density of 1 X 106 cells/100mm tissue culture plate and harvested
48 hours later. Cells were washed twice with ice-cold phosphate buffered saline then
collected using a plastic scraper. Samples were aliquoted into a 15ml conical tube and
centrifuged at 1,500 X g for 10 minutes at 4°C. The cell pellet was resuspended in 500|il
of ice-cold phosphate buffered saline. 500gl of ice-cold buffer Cl and 1.5mls of ice-cold
distilled water was added to the sample to facilitate cell membrane lysis. Samples were
mixed by inversion and incubated on ice for 10 minutes. Next, samples were centrifuged
at 1,300 X g for 15 minutes at 4°C. The supernatant was discarded and 250pl of ice-cold
buffer Cl was added followed by vortexing and centrifugation at 1,300 X g for 15
minutes at 4°C to remove cell debris. The supernatant was discarded followed by the
addition of 1ml of buffer G2. Samples were vortexed vigorously for 30 seconds followed
by the addition of 25 pi of Qiagen protease or Qiagen proteinase K. Samples were then
incubated at 50°C for 1 hour. During this time a Qiagen genomic DNA purification
column 20/G was equilibrated using 1ml of buffer QBT. Samples were vortexed prior to
adding to the purification column. Columns were then washed three times with 1ml of
buffer QC. Genomic DNA was eluted from column using 1ml of buffer QT pre-warmed
to 50°C. Elution was repeated a second time. DNA was precipitated by adding 1.4mls of
100% isopropanol at room temperature to the sample followed by vortexing. Samples
were aliquoted equally into two, 2.0ml nuclease-free tubes and centrifuged at 16,000 X g
at 4°C for 15 minutes in a refrigerated table-top microfuge. Each DNA pellet was
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washed with 1ml of 70% ice-cold ethanol, vortexed and centrifuged at 16,000 X g for 10
minutes at 4°C. The supernatant was removed and DNA pellets were allowed to air-dry
before resuspending samples in 50pl Tris-EDTA, pH 8.0. Samples were incubated
overnight at 50°C and then quantitated by ultraviolet spectophotometry at a 260nm
wavelength.

Cytosine methylation analysis using sodium bisulfite modification of genomic DNA

2pg of purified genomic was modified using the EZ DNA Methylation Kit™
(Zymo Research Corporation, Orange, CA) following the manufacturer’s instructions.
l-2 p g of high quality, purified genomic (free of RNA and protein) DNA was used for
each bisulfite modification reaction. PCR primers used for bisulfite modified DNA
amplification were designed using the MethPrimer program
(http://www.ucsf.edu/urogene/methprimer/) (137). The primers used to amplify a 398
base pair region of the SPARC 5’ promoter region (bisulfite modified) were as follows:
primer 1= 5’ tagttatagattgaattttttgtatttttt 3’, primer 2= 5’ attttattttaaaacaaaatctcactcactcta
3’. The primers used to amplify a 366 base pair region of the SPARC 3’ promoter region
(bisulfite modified) were as follows: primer 1= 5’ ggttagaagattaagatatttgggtttg 3’, primer
2= 5’ caaaaaaccactcaaaactctaaactaa 3’. PCR reactions consisted of 5pi of 10X Titanium
Taq buffer (Clontech Corporation, Palo Alto, CA), 4pl of a dNTP mix (2.5mM each
dATP, dTTP, dCTP, dGTP), 200ng each of primer 1 and primer 2, 0.5pl of Titanium™
Taq DNA polymerase (Clontech Corporation, Palo Alto, CA), and nuclease-free water to
a reaction volume of 48pl. 2pl of bisulfite modified genomic DNA was used as the
template for PCR. Polymerase chain reaction was conducted using a Biometra T-
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Gradient thermocycler as follows: step 1, 95°C for 3 minutes, step 2, 95°C for 45
seconds, step 3, 60°C for 45 seconds, step 4, 68°C for 1 minute. Steps 2-4 were repeated
an additional 32 times. Reactions were subsequently cooled to 4°C and 15pl of each
reaction was analyzed by agarose gel electrophoresis. 0.8% agarose gels in IX TBE were
prepared and stained with ethidium bromide in order to visualize PCR amplification
products by ultraviolet transillumination at 3 12nm. PCR products were gel purified using
a Qiaquick Gel Extraction Kit (Qiagen Corporation, Valencia, CA) following the
manufacturer’s instructions.
Purified PCR products were ligated into the T/A cloning plasmid, pGEMT-Easy
(Promega Corporation, Madison, WI) and transformed into DH5 alpha electrocompetent
E. coli. Individual clones were screened for the presence of an insert of the expected size
by EcoRA restriction enzyme digestion. Plasmid DNA from positive clones was purified
using the Qiagen Plasmid Spin Miniprep Kit (Qiagen Corporation, Valencia, CA)
according to manufacturer’s instructions and eluted in nuclease-free water. DNA from
eight cloned PCR products was sequenced for each cell line. DNA sequences were
aligned and compared to a reference SPARC promoter sequence (GenBank accession
number X82259) in order to determine the methylation status of individual cytosine
residues. Only DNA sequences demonstrating complete conversion of non-CpG
cytosines were used for analysis.

DNA sequencing

DNA sequencing was performed by MWG Biotechnology and the University of
Virginia Core DNA Sequencing Facility unless otherwise stated.
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CHAPTER III
RESULTS

A. Effects of SPARC on MCF7 Cell Phenotype

The purpose of the experiments outlined in this section was to determine the
extent to which SPARC gene expression influences MCF7 cell phenotype. SPARC gene
expression has been correlated with a variety of tumor cell phenotypes including
increased cell motility and invasion, decreased cell adhesion and inhibition of cell
proliferation (101, 104, 105, 107, 123). However, little is known regarding the functional
role of SPARC in regulating breast cancer cell phenotype. In order to gain a better
understanding of these events, we used a MCF7 model system in which overexpression
of the transcription factor c-Jun results in increased SPARC gene expression and
phenotypic changes consistent with malignant progression (46, 51). Many of the
alterations in cell phenotype induced by c-Jun are consistent with known functions of
SPARC, such as increased cell invasiveness. Therefore, we sought to examine the
contribution of SPARC using two approaches. The first was to overexpress SPARC in
MCF7 cells in the absence of exogenous c-Jun overexpression. This approach would
allow us to determine the extent to which SPARC expression is sufficient to induce
alterations in cell phenotype. Our second approach was to inhibit SPARC gene
expression in MCF7 cells stably expressing c-Jun. This strategy would allow us to
determine the contribution of SPARC to c-Jun induced phenotypic changes.
Characterization of these processes will provide a better understanding of the molecular
mechanisms of breast cancer progression.
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Cloning of the human SPARC protein coding region

In order to use a genetic approach to analyze the contribution of SPARC in MCF7
cell phenotype, we first needed to isolate an expressible human SPARC cDNA clone. To
accomplish this goal, we conducted RT-PCR to specifically amplify the full-length
human SPARC protein coding region. Total RNA from c-Jun/MCF7 cells, in which
SPARC is abundantly expressed, was reverse transcribed. The SPARC cDNA was PCR
amplified using a gene specific primer pair which flanked the translation start and stop
codons. Restriction enzyme digestion sites were included at the 5’ ends of each primer to
facilitate directional cloning. The SPARC PCR amplification product was gel purified
and cloned into the pGEM7-Zf+ plasmid. DNA sequencing confirmed the identity of the
cloned PCR product as the full-length SPARC protein coding sequence (Fig. 5).

Expression of the cloned human SPARC gene by in vitro transcription/translation

In order to verify expression of the cloned SPARC gene we conducted in vitro
transcription and translation as shown in Fig. 6. The SPARC/pGEM7-Zf+ plasmid was
linearized with a restriction enzyme 3’ of the stop codon and used as the template for in
vitro transcription reaction using recombinant bacteriophage SP6 polymerase. The
resulting SPARC RNA was in vitro translated using nuclease treated rabbit reticulocyte
lysates in the presence of 35 S-methionine. A negative control mock translation reaction,
in which template was omitted, was also conducted. In vitro translation products were
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
followed by autoradiography in order to detect

35

S-methionine labeled SPARC protein.

As shown in Fig. 6, analysis of in vitro translated SPARC reaction products revealed
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Fig. 5. Summary of the human SPARC protein coding sequence. 912 base pair
nucleic acid sequence of human SPARC protein coding sequence (GenBank
accession number NM_003118) and predicted 303 residue amino acid sequence.
Single letter amino acid abbreviations correspond to IUPAC designation.
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protein coding sequence cloned into pGEM7Zf+ plasmid, linearized, in vitro
transcribed using recombinant bacteriophage SP6 RNA polymerase.
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expression of a 34kDa protein. This molecular weight is consistent with SPARC protein
that has not been post-translationally modified. In vivo, SPARC has been shown to
undergo TV-linked glycosylation at amino acid 99 (Asn) which results in a higher
molecular weight protein product (112, 138, 139). However, in vitro synthesis of
SPARC protein using rabbit reticulocyte lysates is not expected to result in a glycosylated
product. A second, lower molecular weight protein present in the SPARC reaction may
have been generated from an alternate translation start site, since the band is not present
in the mock translation reaction. To our knowledge, there have been no reports of
alternate start site usage for SPARC in vivo, therefore this lower molecular weight
product is most likely an in vitro artifact. Based on DNA sequencing (Fig. 5) and in vitro
transcription/translation analysis (Fig. 6), we conclude that we successfully isolated a
full-length, expressible human SPARC cDNA.

Generation of MCF7 stable cell lines constitutively expressing SPARC

Next we sought to generate MCF7 cell lines stably expressing SPARC in order to
analyze its role in modulating the MCF7 phenotype. To accomplish this goal, we used
retroviral mediated gene transfer to introduce the SPARC gene expression cassette into
MCF7 cells. This strategy was chosen over direct transfection of a SPARC mammalian
expression plasmid for two main reasons. First, the efficiency of gene transfer using
retroviral gene delivery is much higher compared to standard transfection of plasmid
DNA. Second, integration of the transgene into the host cell genome is much more
efficient due to the presence of viral long terminal repeat (LTR) sequences. A schematic
representation of our experimental approach is outlined in Fig. 7. The SPARC protein
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coding region was subcloned into the retroviral expression plasmid, LPCX. This plasmid
was transfected into the PT67 packaging cell line to generate infectious, replication
deficient retrovirus. In parallel, a negative control retrovirus, without the SPARC gene
insert, was also generated. The PT67 packaging cell line stably expresses viral gag,pol
and env genes required for virus assembly (140). The LPCX plasmid transfected into
these cells provided the viral packaging signal sequence. Virus was harvested from PT67
tissue culture media and then used to infect MCF7 cells. Following infection, MCF7
cells were grown in the presence of the antibiotic puromycin to allow for positive
selection of cells containing the stably integrated SPARC or empty vector control gene
expression cassettes. Individual antibiotic resistant stable cell colonies were ring cloned
and assayed for SPARC expression. Expression of the SPARC transgene is regulated via
the cytomegalovirus major immediate early gene promoter. As a result, SPARC is
constitutively expressed at high levels in stable cell clones.
Fig. 8 shows semi-quantitative RT-PCR analysis of steady state SPARC mRNA
levels in three independently isolated stable SPARC/MCF7 cell clones. These results
indicate that SPARC expression in each of the three clones was comparable to the levels
observed in c-Jun/MCF7 cells. Next, SPARC protein expression was analyzed by
Western blot analysis of whole cell lysates using a SPARC specific antibody (Fig. 8).
The molecular weight of SPARC protein was estimated to be 43kDa, consistent with
published reports and consistent with SPARC expressed in c-Jun/MCF7 cells (111, 125,
141). A higher molecular weight band was occasionally observed and may represent
non-specific background due to insufficient washing during the Western blot procedure.
Based on the results presented in Fig. 8, we conclude that three independent
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SPARC/MCF7 stable cell clones were isolated that express levels of SPARC mRNA and
protein comparable to c-Jun/MCF7 cells and would, therefore, be good candidates for
phenotypic characterization.

Effect of stable overexpression of SPARC on MCF7 cell proliferation

Increased SPARC expression has been shown to influence a variety of cell
phenotypes (101-107). For example, increased expression of SPARC is known to inhibit
cell cycle progression resulting in a decrease in cell proliferation (141, 142).
Interestingly, we observe a similar phenotype in c-Jun/MCF7 cells in which SPARC
mRNA and protein levels are dramatically elevated (46, 51). Therefore, we hypothesized
that SPARC may contribute to decreased cell proliferation in our MCF7 model system.
In order to determine if SPARC overexpression, alone, was sufficient to alter the
rate of MCF7 cell proliferation, we conducted non-radioactive cell proliferation assays
(MTT assays). The MTT assay is a colorimetric assay based on cellular conversion of
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl) tetrasodium bromide dye to an
insoluble, blue formazan reaction product (143). The degree of color change in each
sample has been shown to be directly proportional to cell number (143, 144).
Vector control/MCF7, c-Jun/MCF7 and SPARC/MCF7 stable cell lines were
initially maintained in serum-free conditions for 24 hours in order to promote quiescence.
Cells were then trypsinized, counted and plated at an equivalent density in complete
media containing 10% fetal bovine seruni. MTT reactions were quantified by measuring
the optical density (OD) of each sample at 24 hour intervals for a total of 96 hours.
Results were analyzed by linear regression analysis to determine the slope of a best-fit
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line between each optical density reading for each cell line. Proliferation rates for
c-Jun/MCF7 and SPARC/MCF7 cells were then expressed relative to vector
control/MCF7 cells.
As shown in Fig. 9, the three SPARC/MCF7 stable cell lines exhibited a
statistically significant decrease in cell proliferation rate compared to vector control
MCF7 cells (P= <.05). These results are consistent with previous reports which
demonstrated that overexpression of SPARC in the breast cancer cell line,
M DA-M B-231, resulted in a decrease in the cell proliferation rate (142). However,
SPARC/MCF7 cell lines failed to fully recapitulate the cell proliferation defects induced
by c-Jun overexpression. One explanation for this difference is that other c-Jun target
genes contribute to regulation of cell proliferation. Consistent with this notion, we have
previously shown that overexpression of c-Jun results in altered expression of several cell
cycle genes including /;/(5INK4a and/>27CIP1/Wafl (51).

Analysis of in vitro cell motility and invasion in SPARC/MCF7 stable cell lines

As stated previously, increased SPARC expression is associated with increased
cell motility and invasion during wound healing, tissue remodeling and tumorigenesis
(101-107). Consistent with these observations, we have previously shown that MCF7
cells overexpressing c-Jun exhibit a dramatic increase in in vitro cell motility and
invasion (46). In order to determine if SPARC overexpression, alone, was sufficient to
induce cell motility and invasion we assayed SPARC/MCF7 stable cell lines using a
modified Boyden chamber assay. This assay measures the ability of cells to migrate
through a porous membrane in response to a chemotactic stimulus (145).
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Cell Proliferation Rate of SPARC/MCF7 Stable Cell Lines
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Fig 9. Effect of stable SPARC expression on MCF7 cell proliferation. Cell
proliferation rates were determined by MTT assay. The indicated cells lines were
plated at the same density in 96-well plates. Samples were assayed at 24, 48, 72 and
96 hours. Optical densities were determine using a microtiter plate reader rate
determined slope of the line. Clone 1, 2 and 3 represent three independent
SPARC/MCF7 stable cell lines. The cell proliferation rate of vector control/MCF7
cells was set at 100%. The proliferation rate of c-Jun/MCF7 and SPARC/MCF7
cells is expressed as a percentage of MCF7.
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An equal number of vector control MCF7, c-Jun/MCF7 and three SPARC/MCF7 stable
cell lines were suspended in serum-free growth media and added to the upper portion of a
modified Boyden chamber. These cells were separated from the bottom chamber of the
apparatus by a gelatin coated porous membrane. The lower chamber contained NIH3T3
conditioned media which served as the chemotactic stimulus. As a result, cells with the
capacity to respond positively to the chemoattractant migrated through the pores,
ultimately attaching to the underside of the membrane. Following a short (4-5 hour)
incubation, the apparatus was disassembled and the cells were stained. Cells remaining
on the upper portion of the membrane, which did not migrate through pores, were wiped
away and the cells on the bottom were counted using an inverted microscope. Cells in
multiple fields of view were counted in order to control for localized variation in cell
distribution as well as variations in membrane coating.
In vitro cell invasion assays were conducted in a similar manner to the motility
assays. The main difference was that membranes were coated first with collagen IV and
then with Matrigel™. Matrigel™ is a complex mixture of extracellular matrix (ECM)
components obtained from Engelbroth-Holm-Swarm (EHS) mouse sarcoma cell cultures
(146). This mixture polymerizes on the membrane and forms a barrier that cells must
proteolytically degrade in order to migrate through the pore. Therefore, this in vitro
invasion assay is a measure of a cell’s ability to both degrade extracellular matrix
components and move in a directional manner. As shown in Fig. 10, SPARC/MCF7
stable cell lines showed no significant difference in motility or invasion when compared
to vector control/MCF7 cells. These results suggest that other cellular changes induced
by c-Jun are required for acquisition of these phenotypes.
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Fig. 10. Analysis of in vitro cell motility and invasion demonstrated by
SPARC/MCF7 stable cell lines. A, Quantitation of cell motility assays done on
gelatin coated membranes over a four hour incubation period. B, Quantitation of
cell invasion assays conducted on Matrigel™ coated membranes over a period of
four hours. Each motility and invasion experiment was conducted at least three
times. All values are expressed as number of stained cells per high-powered field.
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Analysis o f the effect of SPARC inhibition on c-Jun induced cell motility and
invasion in MCF7 cells

In order to determine if SPARC is involved in migration and invasion exhibited
by c-Jun/MCF7 cells we developed a means for its specific suppression. A previous
study examining the role of SPARC in human melanoma showed that antisense inhibition
of SPARC expression diminished cell adhesion and invasiveness in vitro and abrogated
tumor formation in mice in vivo (126). Therefore, we chose to adopt a similar strategy to
determine the contribution of SPARC to c-Jun induced cell motility and invasion in a
MCF7 breast cancer model system.
In order to express antisense SPARC in c-Jun/MCF7 cells we constructed
replication deficient adenovirus expressing the SPARC cDNA in the antisense
orientation. We chose an adenovirus based strategy for gene delivery because this
method is more efficient compared to standard transfection procedures. This method
results in transient, high levels of expression of the gene of interest. Using this method,
we were able to demonstrate 90% of c-Jun/MCF7 cells expressing the control gene betagalactosidase (Appendix A, Fig. 41). Although this method is limited to transient gene
expression, it is still suitable for in vitro cell motility and invasion assays because these
are short-term assays (4-5 hours). A schematic diagram of our experimental approach is
outlined in Fig. 11.
Recombinant, replication deficient adenovirus was produced in the human
embryonic kidney cell line, HEK293. These cells stably expresses the adenovirus El
genes necessary for viral replication (147, 148). Virus was harvested from HEK293 cells
and used to infect c-Jun/MCF7 cells. Infection of c-Jun/MCF7cells with an adenovirus

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

67

Subclone gene expression cassette into recombinant adenoviral DNA (Clontech
AdenoX™ commercial system)

1.) beta-galactosidase control adenovirus

2.) antisense SPARC adenovirus

Transfect recombinant adenovirus DNA into HEK293 packaging cell line

I

Viral assembly and packaging (HEK293 cells)
Harvest replication deficient recombinant adenovirus

j

Titer viral stocks (plaque assay/Clontech AdenoX Rapid Titre Kit™)
Infect c-Jun/MCF7 cells
Harvest total cell protein
Western blot for SPARC protein
Determine optimal multiplicity of infection (MOI) and time point which result
in decreased SPARC protein levels

i

Assay for in vitro cell motility and invasion

Fig. 11. Experimental approach for suppression of SPARC protein
expression using antisense SPARC adenovirus.
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expressing the beta-galactosidase gene product was used to determine the optimal
multiplicity of infection (MOI) in which most cells became infected without showing
cytotoxic effects. This MOI was subsequently used to infect c-Jun/MCF7 cells with the
adenovirus expressing SPARC in the antisense orientation. SPARC protein expression
was subsequently analyzed by Western blot at 12, 30, 48 and 72 hours post-infection.
Fig. 12 demonstrates a marked inhibition in SPARC protein expression 24 hours
following infection (MOI=5) with antisense SPARC adenovirus. This time point and
MOI was subsequently used to assess motility and invasion of c-Jun/MCF7 cells.
As shown in Fig. 13, c-Jun/MCF7 cells expressing antisense SPARC were
significantly less motile than cells infected with the same MOI of control adenovirus.
Additionally, c-Jun/MCF7 cells infected with the SPARC antisense virus demonstrated a
70% decrease in invasive capacity when compared to control infected cells. Taken
together, these results are consistent with a mechanism by which SPARC upregulation, in
response to c-Jun, is a pivotal event leading to the induction of motility and invasion in
c-Jun/MCF7cells.

Development of a RNAi mediated approach for stable SPARC inhibition in
c-Jun/M CF7 cells

As a follow-up to the transient antisense SPARC studies described above, we
sought to develop a system for stable inhibition of SPARC expression in c-Jun/MCF7
cells for future in vivo studies. Recent breakthroughs have uncovered a novel approach,
termed RNA interference (RNAi), for potent and specific inhibition of gene expression
(149-151). Expression of short, 19-23 base pair, small interfering RNAs (siRNAs) has
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Fig. 12. Analysis of SPARC expression in c-Jun/MCF7 cells infected with
antisense SPARC adenovirus. A, Western blot analysis of SPARC protein
expression at 12, 30, 48 and 72 hours following infection with adenovirus
expressing SPARC in the antisense orientation or control adenovirus expressing
the beta-galactosidase gene (MOI= 5) in c-Jun/MCF7 cells. B, Western blot
demonstrating SPARC expression in c-Jun/MCF7 cells 24 hours post-infection
with antisense SPARC expressing adenovirus. Equal amounts of total protein
(50/rg) were loaded in each lane.
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Fig. 13. Analysis of c-Jun/MCF7 in vitro cell motility and invasion following
antisense inhibition of SPARC expression. A, Quantitation of cell motility assays
done on gelatin coated membranes over a 4 hour incubation period. B, Quantitation
of cell invasion assays conducted on Matrigel™ coated membranes over a period of
4 hours. Each infection and motility/invasion assay was repeated at least three times
and verified using different viral stocks to control for variability in virus
preparations. All values are expressed as number of stained cells counted per highpowered field. Statistics were evaluated using ANOVA (7)=<.005).
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been shown to promote degradation of complementary cellular mRNAs (149, 150, 152,
153). This process occurs via activation of an RNAi nuclease complex termed the RNA
induced silencing complex (RISC). RISC binds to short, double stranded RNA
molecules leading to enzymatic degradation of target mRNA thereby decreasing steady
state levels (149, 154). A schematic representation of our strategy to inhibit SPARC
expression using RNAi is shown in Fig. 14.
One drawback to this method is that it is difficult to predict which sequences will
activate the cellular RISC complex. Therefore, we designed four unique siRNA
expression cassettes targeted to different regions of the human SPARC mRNA. These
expression cassettes were then cloned into the pSilencer-Hl-hygro plasmid. This plasmid
expresses the siRNA sequences under the control of a RNA polymerase III gene
promoter (HI promoter) which has been shown to promote efficient transcription of short
RNA species (34, 155). In addition, the pSilencer-Hl-hygro plasmid contains the
hygromycin resistance gene allowing for positive selection of stable cell clones. Separate
plates of c-Jun/MCF7 cells were transfected with individual SPARC siRNA expression
plasmids followed by selection with hygromycin. Hygromycin resistant cells were
pooled and maintained as stable cell populations. These cell populations were then
analyzed by Western blot to determine SPARC protein levels (Fig. 14). Three of four
siRNA sequences designed to inhibit SPARC expression dramatically lowered steadystate levels of SPARC protein. Importantly, levels of c-Jun protein remained unchanged
(Fig. 14). Therefore, we conclude from these experiments that we have successfully
developed a reagent suitable for inhibiting SPARC protein expression allowing for long
term in vivo analysis of these cells. This RNAi approach for SPARC “knock-down” was
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Fig. 14. Experimental approach and characterization of human SPARC specific
RNAi. A, Schematic representation of the regions of SPARC mRNA targeted by
individual siRNA sequences. B, Design of siRNA sequences and predicted
secondary structure of siRNA transcripts. C, Western blot analysis of SPARC
protein expression in c-Jun/MCF7 cells stably expressing individual SPARC siRNA
sequences (1= +161, 2= +328, 3= +418, 4= +604).
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more dramatic than the results we obtained using the antisense SPARC adenovirus. This
is likely due to the fact that RNAi promotes active degradation of mRNA in contrast to
the antisense SPARC adenovirus.
In summary, the objective of Aim 1 was to determine the role of SPARC gene
expression on MCF7 cell phenotype. We addressed this objective by cloning the human
SPARC gene and expressing it in MCF7 cells to assess the role of SPARC in the absence
of exogenous c-Jun expression. In addition, we expressed SPARC in the antisense
orientation in c-Jun/MCF7 cells in order to inhibit SPARC protein expression. This
allowed us to examine the contribution to c-Jun induced invasive phenotype. Our
conclusions from these experiments were: 1.) SPARC overexpression in MCF7 cells
results in a significant decrease in cell proliferation rate 2.) overexpression of SPARC,
alone, is not sufficient to promote cell motility and invasion of MCF7 cells and 3.)
suppression of SPARC in c-Jun/MCF7 cells significantly inhibits cell motility and
invasion. The results presented in this section establish SPARC as a phenotypically
relevant c-Jun target gene which contributes to a pro-invasive breast cancer cell
phenotype. However the mechanism(s) of SPARC gene regulation by c-Jun had yet to be
examined and served as the focus of Aim 2.
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B. Mapping the c-Jun Responsive Region of the SPARC Promoter

The experiments described in Aim 1 established that SPARC is a phenotypically
relevant c-Jun target gene. Next, we were interested in determining the mechanism(s) by
which SPARC gene expression is regulated. In order to address this issue, we examined
SPARC promoter activity by transient transfection and promoter/reporter assays. In
addition, we characterized protein/DNA interactions involving the SPARC promoter
using nuclear extracts from MCF7 and c-Jun/MCF7 cell lines. The studies conducted in
Aim 2 sought to identify cis regulatory elements of the SPARC promoter which confer
c-Jun responsiveness in the context of a MCF7 breast cancer model system.

Analysis of SPARC promoter activity in vector control/MCF7, JunD/MCF7 and
c-Jun/M CF7 stable cell lines

The human SPARC promoter was originally described as a 1409 base pair
sequence 5’ of the major transcriptional start site (129). This sequence was shown to
exhibit activity by transient promoter/reporter assays in multiple cell lines including
HEK293, HeLa, HepG2, Tera-2 and HT1080 cells (129). Analysis of the human SPARC
promoter sequence revealed the presence of three AP-1 like sites which deviate from the
consensus context (TGAC/GTCA) by a single nucleotide (Fig. 15). Previous studies
conducted by our laboratory have shown that c-Jun/AP-1 is capable of binding to AP-1
like sequences in vitro (80). Therefore, we hypothesized that c-Jun may bind to one, or
more, of these sites as a means of positively regulating SPARC promoter activity.
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Fig. 15. The DNA sequence of the human SPARC gene promoter., +1 denotes the
transcription start site. +2 through +28 denotes additional sequence from the SPARC
gene 5’ untranslated region and is present in the SPARC promoter/luciferase reporter
plasmids used in these studies. AP-1 “like” sites are underlined.
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In order to quantify promoter activity, we assayed the human SPARC promoter cloned
immediately upstream of the firefly luciferase reporter gene (generous gift from Dr. Marc
Castellazzi). This plasmid was transiently transfected into two independent vector
control/MCF7, c-Jun/MCF7 and JunD/MCF7 stable cell lines. JunD/MCF7 cells were
used in order to determine the extent to which SPARC upregulation was specific to c-Jun.
Forty-eight hours after transfection, cellular protein was assayed for luciferase enzyme
activity as a measure of SPARC promoter activity. Luciferase values were normalized to
protein concentration and represented as fold induction over empty vector control/MCF7
cells.
As shown in Fig. 16, transient transfection of the SPARC promoter/luciferase
reporter plasmid (-1409/+28) into c-Jun/MCF7 cells resulted in a 15-30 fold increase in
promoter activity when compared to vector control/MCF7 cells. Overexpression of JunD
had no significant effect on SPARC promoter activity suggesting that SPARC promoter
activation is specific to c-Jun. These results establish that the SPARC promoter is
responsive to c-Jun in the context of a transient promoter/reporter assay and would
therefore serve as a valuable tool in order to map the c-Jun responsive region(s).

Characterization of protein/DNA interactions at the SPARC promoter AP-1 like
sites

Next, we evaluated protein/DNA interactions of three potential AP-1 binding sites
at -1051/-1045, -868/-862 and -241/-235 by gel mobility shift analysis. Oligonucleotide
primers for each of the non-canonical AP-1 sites were generated and assayed for their
ability to bind proteins from nuclear extracts derived from vector control/MCF7,
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Fig. 16. Analysis of SPARC promoter (-1409/+28) activity in MCF7, JunD/MCF7
and c-Jun/MCF7 stable cell lines. A, Schematic diagram indicating the relative location
and DNA sequence context of three non-canonical AP-1 sites. Nucleotides underlined
and in italics denote sequences which differ from the consensus AP-1 context. B,
Results of transient transfection analysis of the SPARC promoter (-1409/+28)/luciferase
reporter plasmid in the indicated cell lines. Promoter activity is expressed as fold
induction over the vector control/MCF7 cells. Relative luciferase values were
normalized to protein concentration. Each experiment was done 2-3 times in triplicate.
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JunD/MCF7 and c-Jun/MCF7 cells. In addition, a consensus AP-1 probe was analyzed
as a positive control for AP-1 binding. Nuclear extracts from each cell line were
incubated with

32

P radiolabeled DNA probes corresponding to the AP-1 like sequences

(Fig. 17). Protein/DNA complexes were resolved on non-denaturing polyacrylamide gels
using conditions previously established for AP-1 binding (80). As a negative control,
each of the radiolabeled DNA probes were also analyzed in the absence of nuclear
extract.
As shown in Fig. 17, only one of the SPARC promoter sites (-1051/-1045)
showed appreciable binding of a complex consistent with AP-1 to proteins from cJun/MCF7 nuclear extracts. The inability to detect binding to the other two AP-1 like
sites at -868/-862 and -241/-235 suggests that these sites are in a poor sequence context
for AP-1 complex formation. We detected minimal AP-1 binding activity in vector
control/MCF7 nuclear extracts, consistent with previous reports that MCF7 cells possess
low endogenous levels of AP-1 activity (95). We also did not detect AP-1 binding in
JunD/MCF7 nuclear extracts, consistent with our previous finding that JunD
overexpression had no effect on SPARC promoter activity (Fig. 16). Taken together,
these results suggest that AP-1 binding activity present in c-Jun/MCF7 nuclear extracts is
capable of recognizing the SPARC promoter AP-1 like site at -1051/-1045.

Gel shift competition analysis of the SPARC promoter AP-1 like site at -1051/-1045

Next, we sought to characterize the specificity of protein/DNA interactions on the
SPARC promoter -1051/-1045 AP-1 like site by conducting gel shift competition
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Fig. 17. Gel mobility shift analysis of the SPARC promoter AP-1 like sites at
-1051/-1045, -868/-862 and -241/-235. The indicated 2P radiolabeled DNA probes
(30,000 cpm) were incubated with either vector control/MCF7, JunD/MCF7 or
c-Jun/MCF7 nuclear extracts (8ug). The arrow (—►) denotes the position of AP-1
complex formation. The asterisk (*) denotes the location of unbound, radiolabeled probe.
MCF7-1 and MCF7-2 designations represent nuclear extracts isolated from individual
stable cell line clones.
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analysis. Gel shift reactions were conducted in the presence of a non-radiolabeled DNA
probe corresponding to an unrelated DNA sequence, without AP-1 binding site, or a
consensus AP-1 sequence. We expected that specific AP-1 binding would not be affected
by addition of an unrelated DNA probe, whereas addition of a consensus AP-1 probe
would inhibit binding in a dose dependent manner.
Nuclear extracts from c-Jun/MCF7 cells were pre-incubated with unlabeled,
“cold” AP-1 consensus gel shift probe or an unrelated competitor DNA sequence. Next,
the 32P radiolabeled probe containing the SPARC AP-1 like site at -1051/-1045 was
added to the reaction. The resulting protein/DNA complexes were resolved on a non
denaturing polyacrylamide gel and visualized by autoradiography. As shown in Fig. 18,
the consensus AP-1 competitor completely abolished AP-1 binding to the -1051/-1045
probe at the lowest concentration whereas competition with an unrelated competitor had a
modest effect only at higher concentrations. Formation of a lower molecular weight
complex decreased with increasing concentrations of either probe suggesting that this
represented a non-specific protein/DNA interaction. Taken together, these results
demonstrate that the non-canonical AP-1 site at -1051/-1045 is capable of binding
proteins with AP-1 binding specificity.

Antibody competition/supershift analysis of the SPARC promoter AP-1 like site at
-1051/-1045

In order to identify proteins which specifically recognized the SPARC promoter
AP-1 like site at -1051/-1045, we performed antibody competition and supershift analysis
(Fig. 19). Addition of antibody to a gel shift reaction can either inhibit specific
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Fig. 18. Gel shift competition analysis of the SPARC promoter -1051 /-1045
AP-1 like site. AP-1 binding from c-Jun/MCF7 nuclear extracts to a radiolabeled
DNA probe (50,000 cpm) containing the non-canonical AP-1 site at -1051/-1045
where (-) represents no competitor followed by increasing amounts of the indicated
AP-1 consensus or unrelated competitors (2.5, 5, 10, 25 and 50X molar excess).
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protein/DNA interactions or result in formation of a higher molecular weight complex
called a “supershift” depending on the protein domain recognized by the antibody. In
either event, this strategy can be used to specifically identify the protein(s) bound to a
radiolabeled DNA probe. Our analysis focused on c-Jun and Fra-1 binding because of
previous observations suggesting that the AP-1 expression profile in these cells favored
this AP-1 dimer combination (Fig. 3) (46).
Nuclear extracts from c-Jun/MCF7 cells were incubated with anti-c-Jun, antiFra-1 or a negative control antibody followed by the addition of the

32

P radiolabeled gel

shift probe (-1051/-1045). As shown in Fig. 19, an antibody directed against the c-Jun
DNA binding domain specifically blocked AP-1 binding indicating c-Jun is part of this
complex. Because this antibody is directed against the DNA binding domain, the effect
seen is a block in binding rather than a supershift (80). Addition of anti-Fra-1 antibody
resulted in the formation of a higher molecular weight, supershifted complex indicating
that the AP-1 binding activity observed is largely composed of c-Jun/Fra-1 dimers.
Incubation with a negative control antibody, against a protein not expected to be present
in the complex (p i6), did not alter AP-1 binding. Taken together, these results
demonstrate that c-Jun/Fra-1 dimers present in c-Jun/MCF7 nuclear extracts are capable
of binding to the SPARC promoter AP-1 like site at -1051/-1045.

Site directed mutagenesis of the AP-1 like site at -1051/-1045 of the SPARC
promoter

In order to determine the functional significance of the AP-1 site located at
-1051/-1045, we conducted site-directed mutagenesis and then analyzed the effect on
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Fig. 19. Antibody competition/supershift analysis of the SPARC promoter
-1051/-1045 AP-1 like site. A, Promoter schematic indicating the position of
several potential AP-1 binding sites in the human SPARC promoter. B, Gel shift
analysis using the indicated nuclear extracts and antibodies run on a 6%
non-denaturing polyacrylamide gel and 50,000 cpm of radiolabeled, double
stranded DNA probe (5’ gcctgggcgacagagtgagtgagactctgtctcaaaac 3’).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

84
AP-1 binding and transactivation. We hypothesized that mutation of this site to a
consensus AP-1 context would result in an increase in DNA binding and a concomitant
increase in SPARC promoter activity. Conversely, we reasoned that mutation of this site,
to a more divergent sequence context, would result in a decrease in AP-1 binding and
transactivation potential.
Gel shift probes were constructed in order to change the wild-type -1051/-1045
sequence to a perfect consensus (TGAGTCA) or triple mutant (CGAATGA) sequence
context. Gel mobility shift analysis of these mutants using c-Jun/MCF7 nuclear extracts
demonstrated that, as expected, mutation to a consensus AP-1 context resulted in much
stronger AP-1 binding, whereas the triple mutant abolished binding (Fig. 20/1).
Next, we examined the effect of these mutations on SPARC promoter activity in
vector control/MCF7 and c-Jun/MCF7 cells. The same point mutations used in gel shift
analysis were introduced in the context of the full-length promoter using overlapping
PCR. Each mutant was subsequently inserted upstream of the firefly luciferase reporter
gene. We reasoned that if this site was critical for promoter activation mediated by direct
AP-1 binding then mutation to a high or low affinity site would result in a change in
transactivation potential relative to the wild-type sequence. On the other hand, if
mutation of this site did not affect promoter activation it would suggest that it is either not
required or not active when taken out of the full genomic context. Interestingly, transient
transfection of the site-directed mutants into c-Jun/MCF7 cells resulted in no significant
difference in promoter activity compared to the wild-type sequence context (Fig. 205).
These results suggest that the AP-1 binding site at -1051/-1045 does not play a critical
role in c-Jun mediated stimulation of SPARC promoter activity.
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Fig. 20. Analysis of AP-1 binding and promoter activity of -1051/-1045 AP-1 like
site mutants. A, Gel shift analysis showing AP-1 binding from c-Jun/MCF7 nuclear
extracts to the indicated mutated or wild type -1051/-1045 DNA probe (30,000 cpm).
B, Site-directed mutagenesis was used to introduce point mutations to the noncanonical AP-1 site at -1051/-1045 in the context of the SPARC promoter fragment
-1409/+28. Mutant and wild-type promoter/reporter constructs were transiently
transfected into c-Jun/MCF7 cells and assayed for activity. Promoter activation is
expressed as percent expression relative to the wild-type sequence context. Relative
luciferase values were normalized to protein concentration.
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Functional analysis of a SPARC promoter deletion mutant spanning the region
from -120/+28

Because mutation of the AP-1 site at -1051/-1045, alone, had no effect on c-Jun
mediated SPARC promoter activation, we initiated deletion analysis in order to examine
the combined effect of removing all three AP-1 like sites. We hypothesized that if AP-1
binding was required then deletion of all potential binding sites would be expected to
abrogate c-Jun responsiveness. To accomplish this, we obtained a SPARC promoter
fragment containing only nucleotides -120 to +28 relative to the transcriptional start site
(generous gift from Dr. Marc Castellazzi). This SPARC promoter construct does not
contain any sequence resembling an AP-1 site and was therefore analyzed in vector
control/MCF7, JunD/MCF7 and c-Jun/MCF7 cells to determine the effect on promoter
activity. Surprisingly, the SPARC promoter fragment spanning from -120 to +28
retained approximately 85% activity relative to the -1409/+28 construct when transfected
into c-Jun/MCF7 cells (Fig. 21). These results suggest that the three AP-1 sequences in
the SPARC promoter are dispensable and that the major c-Jun responsive region is
located within the region spanning -120/+28.

Functional analysis of the SPARC promoter deletion mutant spanning the region
from -70/+28

To further resolve the location of the c-Jun responsive element, we constructed an
additional 5 ’ promoter deletion mutant which resulted in a promoter fragment spanning
from -70/+28 relative to the transcriptional start site. This truncated promoter construct
resulted in deletion of a region containing multiple repeats of the sequence, GGA, and a
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Fig. 21. Analysis of SPARC -120/+28 promoter activity. A, Promoter schematic
indicating features of the region from -120/+28 of the human SPARC promoter. B,
Transient transfection of SPARC promoter (-120/+28)/luciferase reporter constructs
into MCF7 and c-Jun/MCF7 cells. Promoter activation is expressed as fold induction
over the MCF7 cell line. Relative luciferase values were normalized to protein
concentration.
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GC rich region, both of which have been implicated in regulation of SPARC promoter
activity (129, 130, 156, 157). Transient transfection of this construct into c-Jun/MCF7
cells resulted in an 85% reduction in SPARC promoter activity relative to the -120/+28
promoter fragment (Fig. 22). Taken together, these results suggest that the 50 base pair
sequence between nucleotides -120 and -70 contains the major c-Jun responsive region.

Gel shift analysis of the c-Jun responsive region spanning nucleotides -120/-83

Next we wanted to characterize protein/DNA interactions involving the c-Jun
responsive region of the SPARC promoter. As mentioned previously, this region
contains a GC rich element suggesting that transcription factors that recognize this
sequence may play a role in SPARC gene regulation. The transcription factor Spl, and
related proteins, have been shown to bind with high affinity to GC rich regions in TATAless promoters similar to SPARC (140, 158, 159). Therefore, we hypothesized that Spl
may be involved in SPARC promoter regulation via interaction with the GC rich region
located between -120/-83.
We conducted gel mobility shift analysis on vector control/MCF7 and
c-Jun/MCF7 nuclear extracts incubated with a 32 P radiolabeled DNA probed
corresponding to nucleotides -120/-83 of the SPARC promoter. As shown in Fig. 23
analysis of these reactions revealed the presence of similar complexes formed with vector
control/MCF7 and c-Jun/MCF7 nuclear extracts suggesting that a common protein, or
proteins, may be involved.
In order to determine if any of these complexes contained specific Spl binding
activity we conducted competition analysis. Addition of a Spl consensus probe resulted
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reporter constructs into c-Jun/MCF7 cells. SPARC promoter fragment -70/+28 activity
is expressed as percent activation relative to the SPARC promoter -120/+28 luciferase
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Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

90

A
/ \

= GGA repeat

W A A M W W

-A
I
-83

= GC box
-120

B
MCF7 nuclear extracts
c-Jun/MCF7 nuclear extracts
Spl consensus competitor

+
-

-

+

-

+

+
-

anti-Spl antibody

-

-

+ + — — +
— — -

anti-pl30 antibody

-

-

-

Sp 1 mutant competitor

- — -

+
-

-

-

+

+
-

-

-

+ — +

+ +

-

-

+

+

-

-

+

- - — — +

-

-

-

+

+

complex 1 ■
complex 2 ■
complex 3'
non-specific ■
non-specific ■

■I

non-specific ■

unbound probe
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in specific inhibition of complex 1 and complex 3, whereas incubation with a Spl mutant
probe had no effect (Fig. 23). These results suggest that protein with Spl binding
specificity -120/-83 and this activity is present in both extracts.
Next, we attempted to identify Spl as part of complex 1 and/or complex 3 by
antibody shift analysis. As shown in Fig. 23, addition of Spl specific antibody had no
effect on the mobility of any of the specific complexes in either vector control/MCF7 or
c-Jun/MCF7 nuclear extracts under the conditions tested. One explanation for this result
is that another Sp family member, such as Sp2, Sp3 or Sp4, is responsible for the binding
we observe. These related zinc finger DNA binding proteins are all capable of binding to
GC rich sequences similar to those present in the -120/-83 probe (160, 161).
Alternatively, it is possible that Spl is actually present in the complexes, but we could
not detect it using the reaction conditions tested. One final possibility we considered was
that Spl antibody was unable to recognize Spl protein due to protein/protein interactions
which may have masked the epitope(s).

Chromatin immunoprecipitation analysis of c-Jun and Sp-1 binding to the SPARC
promoter in vivo

Next, we wanted to determine if AP-1 and Spl proteins were associated with the
SPARC promoter in vivo. c-Jun and Spl have been shown to interact resulting in
synergistic activation of the p21 and 12(S)-lipoxygenase genes (92, 93). In both cases,
c-Jun/Spl interaction was shown to occur in the absence of an AP-1 binding site (92,
93). Therefore, we hypothesized that, in vivo, c-Jun and Spl may co-localize at the
SPARC promoter as a means of cooperatively regulating its activity.
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Two widely used techniques to study protein/DNA interactions in living cells are
in vivo DNA footprinting and chromatin immunoprecipitation (ChIP) analysis. In vivo
DNA footprinting is a sensitive technique that provides a high degree of resolution for
analyzing protein/DNA interactions (162). However, this technique provides only
indirect evidence regarding the identity of the protein(s) bound to a specific region of
genomic DNA. On the other hand, chromatin immunoprecipitation (ChIP) analysis is a
technique that provides direct evidence that a protein, alone or in a multi-protein
complex, is associated with a specific genomic region in vivo (163, 164). Therefore, we
chose to use chromatin immunoprecipitation analysis to examine c-Jun, Fra-1 and Spl
association with the SPARC promoter in vector control/MCF7 and c-Jun/MCF7 cells.
Our experimental approach is outlined in Fig. 24.
Protein/DNA interactions were “frozen in time” by reversible chemical
crosslinking using formaldehyde. Chromatin was purified and sheared by sonication to
generate fragments with an average size of 500-1000 base pairs. Fragments of this size
provide a high degree of specificity for the genomic DNA region of interest (163, 164).
Following sonication, chromatin was divided into equal amounts to allow for parallel
analysis of multiple protein/DNA interactions. This was accomplished by incubating
individual chromatin aliquots with antibodies for c-Jun, Fra-1, Spl or a negative control
antibody. Following immunoprecipitation, protein/DNA complexes were isolated using
protein A/agarose beads. Samples were then washed to remove non-specific interactions.
Affinity purified chromatin was subsequently eluted from the protein A/agarose beads
followed by crosslink reversal. DNA was then isolated from each sample and analyzed
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by PCR using oligonucleotide primer pairs specific the SPARC proximal promoter
region.
Fig. 25 demonstrates the results of chromatin immunoprecipitation analysis of the
SPARC proximal promoter region. As expected, c-Jun was present at the SPARC
promoter locus only in c-Jun/MCF7 where SPARC gene expression is upregulated. In
addition, Fra-1 was present above background only in c-Jun/MCF7 cells. The presence
of a PCR amplicon in one of the MCF7 “no antibody control” reactions was most likely
due to contamination during PCR since the same sample was tested in other reactions and
did not result in this background. Interestingly, Spl was present at the SPARC promoter
locus in both vector control/MCF7 and c-Jun/MCF7 cell lines consistent with our in vitro
gel shift analysis suggesting the presence of a common protein with Spl binding
specificity. It should be noted that, even though the PCR amplicon spans the region from
nucleotides -241 to +28, we cannot rule out the possibility that AP-1 sites immediately
upstream and/or downstream may contribute to c-Jun and Fra-1 binding observed in the
genomic context. This is due to the fact that the average chromatin fragment size is ~750
base pairs. As a result, we may be detecting protein/DNA interactions occurring 250
base pairs upstream or downstream of the region amplified using the primer pair shown
in Fig. 25.
Taken together, the results presented in Aim 2 demonstrate that the SPARC
promoter region from -120 to -70 contains the major c-Jun responsive element. In
addition, we showed that c-Jun, Fra-1 and Spl were associated with the SPARC proximal
promoter region in c-Jun/MCF7 cells. Interestingly, Spl was also bound to this GC rich
region in vector control/MCF7 cells where transcription is inactive. These results are
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significant because they represent a direct mechanism for c-Jun target gene activation
leading to malignant progression.
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C. Epigenetic Modifications Associated With SPARC Gene Expression

The results obtained in Aim 2 identified a cytosine and guanine rich region of the
SPARC promoter which was critical for c-Jun responsiveness. Further analysis of the
SPARC promoter revealed the presence of multiple cytosines in a cytosine-phosphateguanine (CpG) dinucleotide context. CpG sequences are known to undergo epigenetic
modification via DNA methylation (165-167). Importantly, normal genomic DNA
methylation patterns have been shown to change during tumorigenesis and oncogenic
progression (168-171). Aberrant DNA methylation can lead to gene activation or
repression depending on the context. For example, hypermethylation of the tumor
suppressor gene CDKN2A (pi <5INK4a) results in gene inactivation in many tumors (170,
172, 173). In contrast, hypomethylation of gene regulatory regions correlates with
transcriptional activation (174, 175). Interestingly, a recent study demonstrated a
correlation between hypermethylation of SPARC exon 1 and decreased SPARC
expression in pancreatic cancer cell lines (176). Therefore, we tested the hypothesis that
DNA methylation at the SPARC genomic locus may be involved in regulation of SPARC
gene expression in a MCF7 breast cancer model system.

Analysis of SPARC gene expression following treatment of MCF7 cells with the
DNA methyltransferase inhibitor 5-aza-2’deoxycytidine

CpG methylation is catalyzed by cellular DNA methyltransferase (DNMT)
enzymes (170, 177). Previous studies have demonstrated that selective inhibition of
DNA methyltransferases is sufficient to reverse genomic DNA methylation patterns
leading to reactivation of silenced genes (178-181). Therefore, in order to determine the
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effect o f DNA methylation on SPARC gene expression in MCF7 cells we used a
pharmacological inhibitor of DNA methyltransferase activity, 5-aza-2’deoxycytidine
(5-aza-dC). 5-aza-dC is a cytosine nucleotide analog that becomes incorporated into
newly synthesized DNA (179-181). When incorporated 5’ of a guanine residue,
5-aza-dC irreversibly binds DNA methyltransferase enzymes resulting in demethylation
of genomic DNA (182, 183). We reasoned that if the SPARC promoter locus were
methylated in MCF7 cells, then inhibition of DNA methyltransferase activity would be
expected to result in an increase in SPARC expression.
Vector control/MCF7 and c-Jun/MCF7 cells were grown in the presence or
absence of 5-aza-dC for 60 hours. Following treatment, total RNA was isolated and
SPARC mRNA levels were determined by semi-quantitative RT-PCR. The invariantly
expressed 18S ribosomal subunit served as an internal control to demonstrate that equal
amounts of RNA were assayed in each reaction. As shown in Fig. 26, treatment of
MCF7 cells with 5-aza-dC resulted in a dose dependent increase in steady-state SPARC
message levels. In contrast, 5-aza-dC had no effect on SPARC expression in
c-Jun/MCF7 cells where transcription was already active.
Next, we wanted to determine the time course of SPARC gene activation in
MCF7 cells following treatment with 5-aza-dC. Cells were grown in the presence of the
drug for a total of 72 hours at which point the cells were trypsinized, reseeded and grown
in the absence of 5-aza-dC in order to determine the reversibility of SPARC gene
activation. Total RNA was harvested at 24 hour intervals following the start of 5-aza-dC
treatment and SPARC mRNA levels analyzed by semi-quantitative RT-PCR. As shown
in Fig. 26
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Fig. 26. Analysis of SPARC gene expression following treatment of MCF7
cells with the DNA methyltransferase inhibitor, 5-aza-2’deoxycytidine. A, Semiquantitative RT-PCR analysis of SPARC expression in vector control/MCF7 and
c-Jun/MCF7 cells following 5-aza-dC treament at the indicated dose. Cells were
treated with increasing doses of 5-aza-dC for 60 hours. Total RNA was then
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SPARC expression was detected as early as 24 hours after treatment. Surprisingly,
SPARC expression persisted in MCF7 cells exposed to 5-aza-dC even after removal of
the drug. We reasoned that removal of 5-aza-dC would result in restoration of DNMT
activity and, therefore, re-silencing of SPARC expression. One possible explanation for
these results is that SPARC mRNA is very stable and therefore, not quickly degraded.
As a result, steady state message levels may persist even after repression of SPARC gene
transcription. However, this explanation seems unlikely because comparable levels of
SPARC transcript were maintained for up to 60 days after 5-aza-dC removal (Fig. 26).
An alternative explanation is that DNMT inhibition led to SPARC promoter
demethylation that was not re-established following removal of the drug.
Taken together, the results presented in Fig. 26 suggest that, in MCF7 cells,
SPARC gene expression is repressed by DNA methylation and activated following DNA
demethylation. Therefore, we have identified two events which are capable of activating
SPARC gene expression 1.) overexpression of c-Jun and 2.) inhibition of DNA
methyltransferase activity.

Low resolution analysis of SPARC promoter DNA methylation in vector
control/MCF7 and c-Jun/MCF7 stable cell lines

Since inhibition of DNA methyltransferase activity with 5-aza-dC resulted in an
increase in SPARC gene expression, we wanted to determine the extent to which the
SPARC promoter region was methylated in MCF7 cells. In addition, we wanted to
determine if there was a correlation between SPARC promoter methylation and
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transcriptional up-regulation in response to c-Jun. It was our hypothesis that the SPARC
promoter was methylated in MCF7 cells, but not in c-Jun/MCF7 cells.
A variety of different methods have been used to determine genomic DNA
methylation patterns. These include: cleavage of genomic DNA with methylation
sensitive restriction enzymes followed by Southern blot analysis, methylation specific
PCR (MSP) and bisulfite DNA sequencing (172, 184, 185). For our initial experiments,
we conducted PCR analysis of genomic DNA that had been digested with the
methylation sensitive restriction enzyme isoschizomer pair, Hpall and Mspl. Both
enzymes recognize the sequence 5’-CCGG-3’, however, Hpall cannot digest DNA when
the internal cytosine is methylated whereas Mspl will digest regardless of the methylation
status (186). Examination of the SPARC promoter sequence revealed the presence of
four Hpall/MspI sites located at both distal and proximal regions. As a result, this
approach allowed a rapid determination of DNA methylation at four positions over a
1400 base pair region. Our experimental approach is outlined in Fig. 27.
Genomic DNA was isolated from vector control/MCF7 and c-Jun/MCF7 cells and
digested in parallel with Hpall or Mspl. Undigested genomic DNA served as a positive
control for the PCR reactions while Mspl digested samples served as a positive control to
demonstrate complete digestion of the genomic DNA. Additionally, we analyzed
genomic DNA from three independent clones of each cell line to control for clonal
variability.
As shown in Fig. 28, analysis of undigested genomic DNA resulted in successful
PCR amplification of the SPARC promoter indicating that reaction conditions were
optimal. In addition, analysis of Mspl digested samples showed successful digestion of
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Experimental approach for low resolution mapping of SPARC promoter methylation
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by Hpall/MspI mapping. A, Schematic representation of the SPARC promoter
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it is protected from digestion and is therefore methylated. Mspl reactions serve as
controls to demonstrate complete DNA digestion. UC= uncut, and serves as a positive
control for the PCR reaction. The (-) lane serves as a negative PCR control in which
template DNA has been left out of the reaction.
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all Hpall/MspI sites as indicated by the decrease in PCR amplification product. The
presence of low-level background in some Mspl digested samples was most likely due to
incomplete digestion of genomic DNA. PCR analysis of Hpall reactions in vector
control/MCF7 cells resulted in productive amplification suggesting that each of the four
Hpall/MspI sites is methylated. In contrast, analysis of Hpall digested DNA from three
c-Jun/MCF7 stable cell lines resulted in loss of the PCR amplification product at
Hpall/MspI sites #3 and #4. This result indicates that sites #3 and #4 are not methylated
in vivo in c-Jun/MCF7 cells. Further analysis revealed that the distal Hpall/MspI sites,
#1 and #2, remain methylated in all three c-Jun/MCF7 cell lines. Interestingly, the
Hpall/MspI site #4 is located within the -120/-70 region that we previously mapped as
the major c-Jun responsive region. Taken together, these results demonstrate a localized
demethylation of the proximal promoter region in c-Jun/MCF7 cells whereas the distal
promoter region is methylated in both vector control/MCF7 and c-Jun/MCF7 cells.

High resolution analysis of SPARC promoter DNA methylation in vector
control/MCF7 and c-Jun/MCF7 stable cell lines

The previous Hpall/MspI mapping of SPARC promoter methylation
demonstrated that at least two CpG sites become demethylated in response to c-Jun. This
demethylation correlates with c-Jun induced transcriptional activation. However, there
are other CpG sites, not in a Hpall/MspI context, that may also be differentially
methylated. Therefore, we next wanted to determine the methylation status of other CpG
sites in order to generate a more detailed map of SPARC promoter methylation.
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In order to accomplish this goal, we analyzed methylation using sodium bisulfite
modification of genomic DNA followed by DNA sequencing. This method is considered
the “gold standard” for methylation mapping because it allows for single nucleotide
resolution as well as simultaneous analysis of multiple sites on the same fragment of
DNA (185). A schematic diagram of our approach is shown in Fig. 29. Genomic DNA
was treated with sodium bisulfite, hydroquinone and sodium hydroxide to chemically
convert unmethylated cytosines to uracil (185). Methylated cytosines are resistant to this
chemical modification. As a result, it is possible to use DNA sequence analysis to
determine the CpG methylation status of the genomic region of interest. Importantly,
conversion of all non-CpG cytosines to uracil is used as an internal control to verify that
the modification reaction was successful. Following bisulfite modification, genomic
DNA served as the template for PCR using primer pairs specific for distal and proximal
regions of the SPARC promoter. PCR products derived from modified vector
control/MCF7 and c-Jun/MCF7 genomic DNA were then cloned into the T/A cloning
plasmid, pGEMT-Easy. Eight cloned PCR products from each cell line were analyzed by
DNA sequencing. Each of the cloned inserts represents a single allele amplified from a
single cell. As a result, sequencing of multiple clones makes it is possible to determine
the percentage of alleles in the cell population which display a given pattern of
methylation (185).
The results of bisulfite sequence analysis are graphically represented in Fig. 30.
Filled (black) circles indicate methylated CpG residues, whereas empty (white) circles
represent unmethylated CpGs. Strikingly, these results demonstrate prominent
demethylation of the SPARC promoter in c-Jun/MCF7 cells. This demethylation is
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Experimental Approach for High Resolution Mapping of SPARC Promoter Methylation
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Fig. 29. Experimental approach for high resolution mapping of SPARC promoter
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Fig. 30. Results of high resolution, sodium bisulfite mapping of SPARC
promoter methylation. Genomic DNA was isolated from MCF7 empty vector
control cell line and c-Jun/MCF7 stable cell line. DNA was treated with sodium
bisulfite, hydroquinone and sodium hydroxide in order to convert unmethylated
cystosine residues to uracil. Methylated cytosines are protected from chemical
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the SPARC promoter were then PCR amplified, cloned into plasmid DNA and
sequenced. Results are represented graphically where unfilled (white)
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localized to the proximal promoter region and includes the c-Jun responsive region.
These results are consistent with our Hpall/MspI methylation mapping experiments (Fig.
28), in which the two Hpall/MspI sites closest to the transcriptional start site were
demethylated in c-Jun/MCF7 cells. Taken together, the results of SPARC promoter
methylation mapping clearly demonstrate an inverse correlation between SPARC
transcript levels and the extent of DNA methylation.

Analysis of the effect of in vitro methylation on SPARC promoter activity

Next, we wanted to determine the functional significance of SPARC promoter
methylation. It was unclear whether methylation played a functional role in SPARC
promoter regulation or whether the change in methylation was a byproduct of
transcriptional activation.
In order to address this issue, we conducted in vitro methylation of the SPARC
promoter -120/+28 luciferase reporter plasmid and assayed for activity by transient
transfection. There is a single CpG in the c-Jun responsive region between -120/-70
which corresponds to a Hpall sequence context. Purified plasmid DNA was incubated
with recombinant bacterial Hpall methylase in the presence of the methyl donor,
S-adenosyl methionine (SAM). This resulted in methylation of Hpall/MspI site #4 in the
c-Jun responsive region as well as additional sites within the plasmid (Fig. 31). As a
control, we prepared a corresponding mock methylated plasmid in which the Hpall
methylase was omitted from the reaction. In order to verify the completeness of in vitro
methylation, an aliquot of Hpall methylated or mock methylated plasmid DNA was
analyzed by Hpall and Mspl restriction enzyme digestion. Fig. 31, demonstrates that the
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Fig. 31. In vitro Hpall methylation of the SPARC promoter (-120/+28)
luciferase reporter plasmid. A, Schematic representation of all Hpall/MspI sites
in the -120/+28 SPARC promoter/luciferase reporter plasmid. CCGG denotes the
relative location of Hpall/MspI digestion sites in the pGL2 luciferase reporter
plasmid. B, Verification of complete Hpall methylation of the SPARC
promoter/reporter plasmid. Mock methylated and Hpall methylated plasmids
were digested with Hpall or MspI restriction enzyme and analyzed by agarose gel
electrophoresis. U= undigested, H= Hpall digested, M= MspI digested.
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in vitro methylated plasmid was completely protected from Hpall digestion indicating
that it was efficiently methylated.
Next, mock methylated and Hpall methylated SPARC promoter/luciferase
reporter plasmids were transiently transfected into vector control/MCF7 and c-Jun/MCF7
cells. Forty-eight hours post-transfection, luciferase values were analyzed as a measure
of SPARC promoter activity. As shown in Fig. 32, in vitro Hpall methylation of the
SPARC promoter (-120/+28)/luciferase reporter plasmid resulted in an 85% decrease in
promoter activity in c-Jun/MCF7 cells compared to the mock methylated plasmid. This
level of inhibition was similar to the level observed when we deleted the 50 base pair
c-Jun responsive region (Fig. 22). As expected, in vitro methylation had no effect on
SPARC promoter activity in MCF7 cells. Taken together, these results suggest a
functional role for SPARC promoter methylation in regulating c-Jun responsiveness.

Analysis of the effect of in vitro SPARC promoter methylation on protein/DNA
interactions

DNA methylation has been shown to affect transcription by a variety of
mechanisms. For example, cytosine methylation can directly inhibit transcription factor
binding due to alteration of DNA structure (187, 188). In addition, methylated CpG
sequences can serve as recognition sites for methyl binding proteins (189, 190). This can
result in competition between sequence specific transcription factors and methyl binding
proteins for a common DNA sequence (190). Lastly, methyl binding proteins have been
shown to participate in active transcriptional repression via recruitment of histone
deacetylase (HDAC) enzymes (190, 191).
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Fig. 32. Effect of in vitro SPARC promoter methylation on promoter activity in
transient transfection assays. Mock and Hpall methylated plasmids were transfected
into vector control/MCF7 and c-Jun/MCF7 cells. Luciferase activity was determined
for each sample 48 hours post-transfection. Fuciferase values were normalized to
protein concentration for each sample and expressed as relative luciferase units/ug of
protein. Values represent the average of two independent experiments with each
condition tested in duplicate.
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In an attempt to characterize the mechanism(s) by which DNA methylation affects
SPARC promoter activity, we analyzed the effect of in vitro methylation on protein/DNA
interactions by gel mobility shift analysis. We hypothesized that DNA methylation may
alter protein/DNA interactions at the c-Jun responsive region.
Since our previous gel shift analysis of the -120/-83 region (Fig. 23) did not take
into account DNA methylation we re-analyzed this region using mock methylated and
Hpall methylated gel shift probes. In order to verify complete methylation of the probe,
samples were digested with Hpall and MspI restriction enzymes and analyzed by native
polyacrylamide gel electrophoresis. Fig. 33 demonstrates that the in vitro methylated
probe was completely protected from digestion with Hpall restriction enzyme indicating
efficient methylation under these conditions.
Next, in vitro methylated and mock methylated probes were analyzed in gel
mobility shift assays using nuclear extracts from vector control/MCF7 and c-Jun/MCF7
cells. As shown in Fig. 33, similar band shift patterns were formed with either nuclear
extract regardless of the DNA methylation status of the probe. This suggests that in vitro
protein/DNA interactions at the c-Jun responsive region are unaffected by methylation of
Hpall site #4. Based on our previous gel shift competition analysis (Fig. 23) and
chromatin immunoprecipitation data (Fig. 25) we believe these complexes to be
consistent with Sp family protein/DNA interactions. Interestingly, studies by other
laboratories have demonstrated that Spl DNA binding is unaffected by cytosine
methylation (192). It should be noted that we did not attempt antibody shift analysis for
Spl in these experiments because we were previously unsuccessful using this approach
(Fig. 23). In addition, we did not conduct antibody shift analysis for c-Jun/AP-1 binding
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Fig. 33. Effect of in vitro methylation of the SPARC promoter -120/-83
region on protein/DNA interactions. A, DNA sequence of the gel shift probe used
for in vitro methylation analysis. The cytosine residue targeted for methylation
using recombinant Hpall methylase is indicated by (-CH3). B, Hpall and MspI
control digestion reactions demonstrating complete Hpall methylation of the gel
shift probe. C, Gel shift reactions using mock or Hpall methylated gel shift
probes and MCF7 and c-Jun/MCF7 nuclear extracts.
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because there was no AP-1 binding site present in the sequence -120/-83. Taken
together, our data suggests methylation of the c-Jun responsive region does not inhibit the
formation of similar complexes present in both MCF7 and c-Jun/MCF7 nuclear extracts.

Analysis of histone modifications at the SPARC promoter locus

Genomic DNA is arranged in the nucleus as a highly ordered chromatin structure
consisting of repeating protein/DNA complexes called the nucleosome (193, 194). A
single nucleosome consists of 146 base pairs of DNA coiled around an octameric
arrangement of core histone proteins (194-196). This histone core consists of two
molecules each of histones H2A, F12B, H3 and H4 (195, 197). Histones H3 and FI4 are
oriented with the amino terminal protein “tails” radiating outward from the nucleosome
core (195). A variety of post-translational modifications are known to occur at these
“tail” regions including, acetylation, methylation, phosphorylation, and ubiquitylation
(198, 199). Each of these modifications has been associated with either positive or
negative regulation of gene expression (200-202). This has led to the “histone code”
hypothesis proposed by Allis and Jenuwein which puts forth the idea that the
combination of histone tail modifications at a given genomic locus defines the spectrum
of transcriptionally active and repressed states (203).
Histone acetylation is a well-characterized modification associated with gene
regulation (204, 205). Steady-state histone acetylation patterns are reflective of the
balance between histone acetyltransferase (HAT) and histone deacetylase (HDAC)
activities. For example, hyperacetylation of histone H3 and H4 has been shown to
correlate with increased gene expression, whereas hypoacetylation is associated with
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transcriptional repression (199, 201, 206-212). Interestingly, many of the same lysine
residues that have been shown to be acetylated can also be methylated (199, 201, 206). A
single lysine can be either acetylated or methylated at a given time, but not both. In
contrast to acetylation, histone methylation can occur in mono-, di-, or tri-methylated
forms (213, 214). Methylation of histone H3 at lysine 4 (K4) is generally associated with
gene activation while methylation of histone H3 at lysine 9 (K9) is associated with gene
silencing (215-219). Therefore, we expected to see enrichment of methylated histone H3
at lysine 4 in c-Jun/MCF7 cells, whereas in vector control/MCF7 cells we expected to see
methylated histone H3 at lysine 9. In addition, we hypothesized that histones associated
with the SPARC promoter would be hypoacetylated in MCF7 cells compared to
c-Jun/MCF7 cells.
In order to address this hypothesis, we conducted chromatin immunoprecipitation
(ChIP) analysis using modification state specific, anti-histone antibodies. A summary of
the antibodies used in these studies is shown in Fig. 34. In vivo protein/DNA interactions
were analyzed following formaldehyde cross-linking of vector control/MCF7 and
c-Jun/MCF7 cells. Chromatin from each cell line was isolated and fragmented by
sonication. Antibodies were added to diluted chromatin in order to immunoselect
protein/DNA complexes specific for individual histone modifications. An antibody
specific for HER2/«ew, a transmembrane receptor protein not expected be at the SPARC
promoter, was included as a negative control. In addition, an aliquot of sonicated and
crosslinked chromatin was retained and not subjected to immunoprecipitation. This
“input” sample was therefore representative of the amount of total chromatin in each
immunoprecipitation reaction. Protein/DNA complexes were affinity purified using
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Fig. 34. Schematic representation of histone modifications analyzed by chromatin
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the amino terminus.
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protein A/agarose beads. Samples were extensively washed to remove non-specific
interactions followed by elution of the immunoselected chromatin. Protein/DNA
crosslinks were reversed and the DNA purified. This DNA served as the template for
PCR analysis using a primer pair specific for the SPARC proximal promoter region.
PCR was conducted using conditions previously shown to be dependent on the amount of
input DNA (Fig. 35) and therefore quantitative. PCR amplification products were
resolved by agarose gel electrophoresis and quantitated by densitometry. Results were
interpreted by comparing the ratio of individual immunoprecipitated DNA signals to the
corresponding input DNA signal. The values obtained for each antibody were then
compared between cell lines in order to calculate the fold enrichment of each histone
modification in c-Jun/MCF7 cells relative to vector control/MCF7 cells.
As shown in Fig. 35, we detected a 2.7 fold enrichment of di-acetylated histone
H3 (K9, K14) and a 1.8 fold enrichment of tetra-acetylated histone H4 (K5, K 8, K12,
K16) at the SPARC promoter region in c-Jun/MCF7 cells relative to vector
control/MCF7 cells. Additionally, c-Jun/MCF7 cells demonstrated a 2.8 fold increase in
di-methyl histone H3 at lysine 4. Under the conditions tested, we did not observe
methylation of histone H3 at lysine 9, a modification strictly associated with constitutive
heterochromatin and gene silencing (214, 220, 221). Flowever, we did detect this
modification at other genomic loci indicating that the antibody is functional under the
conditions tested (Appendix A, Fig. 45).
Taken together, these results demonstrate that the SPARC promoter locus is
enriched for histone modifications in c-Jun/MCF7 cells that are consistent with active
transcription. However, we were surprised to find these same modifications at the
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Fig. 35. Chromatin immunoprecipitation analysis of histone modifications at the
SPARC promoter locus in MCF7 and c-Jun/MCF7 cells. A, Schematic diagram of
the SPARC promoter indicating the location of ChIP PCR primers. B, Results of
PCR analysis of the SPARC promoter region using immunoselected chromatin from
vector control/MCF7 and c-Jun/MCF7 cells. Chromatin was immunoprecipitated
using the indicated antibodies. PCR amplification products were quantitated by
densitometry. The ratio of each immunoprecipitated reaction product, relative to the
input chromatin sample, was calculated for each antibody and each cell line. This
value was arbitrarily set at one for vector control/MCF7 cells. The corresponding
samples from c-Jun/MCF7 cells were then expressed as fold enrichment relative to
vector control/MCF7 cells. NAC= no antibody control, IP= immunoprecipitated
sample, N/A= quantitation could not be done because the signal for IP reactions was
not above background.
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transcriptionally inactive SPARC locus in MCF7 cells. We interpret these results to
mean that there are subtle differences in histone modifications between vector
control/MCF7 and c-Jun/MCF7 cells. This interpretation would be consistent with the
localized demethylation of the SPARC promoter observed in c-Jun/MCF7 cells.

Analysis of SPARC expression in MCF7 cells treated with the histone deacetylase
inhibitor, trichostatin A

To further characterize the role of histone modification on SPARC gene
expression we examined the effect of the histone deacetylase inhibitor, trichostatin A
(TSA). TSA has been shown to induce hypoacetylation of histones resulting in an
increase in gene expression (222). Furthermore, TSA used in conjunction with the DNA
methyltransferase inhibitor, 5-aza-dC, has been shown to result in synergistic activation
of transcriptionally silenced genes (223-225).
Vector control/MCF7 were treated with vehicle, 5-aza-dC alone, TSA alone, or a
combination of 5-aza-dC and TSA. RNA was then harvested and assayed for SPARC
expression by semi-quantitative RT-PCR. As shown in Fig. 36, 5-aza-dC treatment was
sufficient to induce SPARC gene expression. This result was consistent with our
previous results (Fig. 26) which demonstrated a dose dependent increase in SPARC gene
expression following 5-aza-dC treatment. In contrast, treatment of MCF7 cells with TSA
alone did not result in an increase in steady-state SPARC mRNA levels. When the DNA
methyltransferase inhibitor (5-aza-dC) and histone deacetylase inhibitor (TSA) were used
in combination, we saw no additive or synergistic effect on SPARC gene expression.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

120

MCF7
AZA
AZA
TSA
UT | TSA |
SPARC
18S

Fig. 36. Analysis of SPARC expression in MCF7 cells following treatment
with the histone deacetylase inhibitor, trichostatin A. Cells were treated with
vehicle, 5-aza-dC (5uM), trichostatin A (lOOng/ml), or a combination of
5-aza-dC (5uM) and trichostatin A (lOOng/ml). Total RNA was isolated from
each sample and analyzed by for SPARC expression by semi-quantitative
RT-PCR. UT= untreated, AZA= 5’aza-2’deoxycytidine, TSA= trichostatin A,
(-)= negative RT-PCR control in which template was omitted from the
reaction.
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Taken together, these results suggest that DNA methylation, not histone acetylation, is
the critical epigenetic determinant associated with SPARC gene expression.
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CHAPTER IV
DISCUSSION

The gene, SPARC, is highly expressed in many types of cancer, including tumors
of the breast. Importantly, SPARC has been shown to directly contribute to
tumorigenesis and malignant progression. We have previously shown that constitutive
expression of the transcription factor c-Jun results in SPARC gene activation and
phenotypic progression in a MCF7 breast cancer model system. The studies described in
this dissertation addressed two primary objectives: 1.) to determine the contribution of
SPARC to c-Jun induced phenotype in a MCF7 breast cancer model system, and 2.) to
determine the mechanisms by which c-Jun regulates SPARC gene expression. In this
chapter we will summarize our findings and discuss the results in the context of the
literature.

A. The Effects of SPARC on MCF7 Cell Phenotype
Cell Proliferation

The goal of Aim 1 was to determine the effects of SPARC gene expression on
MCF7 cell phenotype. Several studies have shown that SPARC is associated with
decreased cell proliferation (101, 107, 108). In support of this observation, SPARC
expression is inversely correlated with cell proliferation rate in c-Jun/MCF7 cells.
Flowever, it was unclear which c-Jun target gene(s) may play a role in regulating this
phenotype. In order to address this question, stable cell lines were generated in order to
address the extent to which overexpression of SPARC, alone, is sufficient to inhibit
MCF7 cell proliferation. The results presented in Fig. 9 demonstrate that constitutive
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overexpression of SPARC in MCF7 cells results in an intermediate cell proliferation rate
compared to vector control/MCF7 cells and c-Jun/MCF7 cells. Importantly, the results
were statistically significant (P= <.05) in each of the three SPARC/MCF7 stable cell
lines tested.
The exact mechanism by which SPARC alters cell proliferation remains unclear.
One possibility is that SPARC attenuates cell signaling required for tumor cell
proliferation. In support of this hypothesis, SPARC has been shown to inhibit growth
factor receptor signaling via interaction with platelet derived growth factor (PDGF)
receptor and vascular endothelial growth factor (VEGF) receptor (102, 104, 117).
Another possibility is that altered expression of other c-Jun regulated genes is needed in
order to achieve the same level of inhibition seen in c-Jun/MCF7 cells. For example,
expression of genes involved in cell cycle regulation, such as p l6 mK4a and p 2 yCIP1/Wafl
may provide an additional effect, in addition to SPARC, resulting in decreased cell
proliferation (51).

Cell Motility and Invasion

Next, SPARC/MCF7 stable cell lines were analyzed for their in vitro migratory
and invasive potential. Previous studies have shown that increased SPARC expression
promotes an intermediate attachment state which facilitates cell movement (103, 127).
The processes of directional movement and degradation of reconstituted basement
membrane are essential steps for tumor invasiveness and malignant progression. These
processes are also mechanistically coupled. In order for a cell to exhibit invasiveness it
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must be both motile and exhibit increased proteolytic activity in order to break through a
reconstituted basement membrane.
In Figure 10, we demonstrate that overexpression of SPARC, in the absence of
exogenous c-Jun, is not sufficient to promote MCF7 cell motility and invasion in vitro
(Fig. 10). This result is in agreement with a previous study which showed that addition
of recombinant SPARC to MCF7 cells also failed to promote invasiveness (226).
Next, we addressed the question of whether SPARC expression was required for
c-Jun induced cell motility and invasion. To accomplish this goal, an antisense approach
was used to inhibit SPARC expression. This approach resulted in a transient decrease in
SPARC protein levels (Fig. 12). This decrease in SPARC expression also correlated with
a statistically significant decrease in c-Jun induced cell motility and invasion (Fig. 13).
These results are consistent with a previous report using a mouse model of malignant
melanoma. In this previous study, inhibition of SPARC expression reduced tumor cell
invasiveness in vitro and abrogated tumor formation in mice in vivo (126).
From our studies, it appears that other c-Jun target genes cooperate with SPARC
to promote an invasive phenotype. For example, c-Jun/AP-1 has been shown to stimulate
expression of the matrix metalloproteases (MMPs). Transient transfection of c-Jun in the
invasive breast cancer cell line, MDA-MB-231, stimulates both MMP-2 and MMP-9
expression (227). Furthermore, MMP-9 enzymatic activity was shown to be increased in
c-Jun/MCF7 stable cell lines (46). In addition, SPARC enhances MMP-2 proteolytic
activity in two invasive breast tumor cell lines (MDA-MD-231 and BT549) as well as the
invasive prostate cancer cell lines PC3 and DU145 (226). We hypothesize that SPARC
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may be acting in an autocrine and/or paracrine fashion enhancing both MMP expression
as well as MMP activation thereby contributing to invasiveness.
However, increased MMP expression may not account for enhanced cell motility.
It is possible that expression levels of SPARC modulate cell attachment, thereby,
contributing to altered cell motility. SPARC is known to function as an anti-adhesive
protein and expression correlates with decreased focal adhesion contacts (102, 104, 119).
It is thought that if the cell were too firmly attached to the substratum then cell migration
would be inhibited. Conversely, if the cell were too loosely attached, then the cell may
undergo apoptosis or anoikis. Since we observe inhibition of both motility and invasion,
it is unclear whether this is the result of decreased motility alone or also due to decreased
proteolytic activity. Future studies using an approach such as gel zymography analysis
would be useful in determining the extent to which SPARC regulates MMP enzyme
activity. Taken together, the cell proliferation and motility/invasion data are consistent
with the hypothesis put forth by Giese and colleagues that tumor cells can “grow” or
“go”, but cannot do both simultaneously (118, 228).

B. SPARC Promoter Regulation
Mapping the c-Jun Responsive Region

Having established that SPARC is a phenotypically relevant c-Jun target gene, we
turned our attention to the regulation of SPARC gene expression. The goals of Aim 2
were to map the c-Jun responsive region(s) of the human SPARC promoter and to
identify the trans acting factors which contribute to differential SPARC gene activation.
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A previous study defined the SPARC promoter as the 1409 base pairs 5’ of the
transcriptional start site (129). This promoter region was cloned upstream of a luciferase
reporter gene and assayed by transient transfection. Figure 16 demonstrates increased
SPARC promoter activity in c-Jun overexpressing cell lines, but not empty vector
control/MCF7, or JunD/MCF7 cells. These results are consistent with our previous
observation that overexpression of JunD did not result in an increase in SPARC gene
expression (131). Therefore, we conclude that the related JUN family members, c-Jun
and JunD, differ in their ability to regulate SPARC promoter activity.
The direct model of c-Jun/AP-1 mediated transcriptional regulation involves
dimerization, followed by DNA binding to an AP-1 site and subsequent recruitment of
transcriptional coactivators. The culmination of these events is thought to result in
stabilization of the transcription pre-initiation complex (53, 61, 70, 96, 99). Sequence
analysis of the human SPARC promoter revealed three potential AP-1 binding sites that
differed from a consensus context by a single nucleotide. Gel mobility shift analysis was
used to examine AP-1 binding activity in empty vector control/MCF7, JunD/MCF7 and
c-Jun/MCF7 nuclear extracts. The results demonstrated AP-1 binding only to the
—1051/—1045 site and only in c-Jun/MCF7 nuclear extracts (Fig. 17). These results are
consistent with our previous promoter/reporter data which showed that c-Jun upregulated
the SPARC promoter, but JunD did not. This is also consistent with the relative AP-1
binding activity in c-Jun/MCF7 and JunD/MCF7 nuclear extracts when assayed using a
consensus AP-1 element (Appendix A, Fig. 39). The specificity of binding to the
—1051/—1045 site was demonstrated by oligonucleotide competition analysis using a
consensus AP-1 probe. The results shown in Fig. 18 demonstrated that the major shifted
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complex was consistent with AP-1 and this was confirmed using antibodies specific for
c-Jun and Fra-1 (Fig. 19). These results suggested a direct role for this site in mediating
c-Jun activation of the SPARC promoter. In addition, this result suggests that the other
two AP-1 sites (-868/-862 and -241/-235) are not in a favorable sequence context, most
likely due to the effects of sequences flanking the core binding site.
c-Jun and Fra-1 are upregulated in invasive breast cancer cell lines and clinical
tumor samples (20, 44). Furthermore, c-Jun and Fra-1 appear to be the preferred dimer
combination in this MCF7 model system when c-Jun is overexpressed (Fig. 19 and
Appendix A, Fig. 39). The functional importance of increased Fra-1 expression was
recently shown in a study which demonstrated that overexpression of Fra-1 was sufficient
to promote invasiveness in vitro (229). Conversely, inhibition of Fra-1 expression by
RNAi resulted in decreased invasiveness exhibited by the MDA-MB-231 breast cancer
cell line (229). Future studies using a similar RNAi approach in the MCF7 model system
would be useful in determining the role of c-Jun/Fra-1 heterodimers in regulating SPARC
gene expression and malignant phenotype.
Next, in order to determine the contribution of the -1051/-1045 AP-1 binding site
to SPARC promoter regulation, point mutations were made to the core binding sequence.
As expected, mutation of this site to a consensus context resulted in increased AP-1
binding in gel mobility shift assays (Fig. 20). Conversely, altering the site so that two
additional nucleotides were mutated resulted in a decrease in AP-1 binding (Fig. 20). We
reasoned that if the AP-1 site played a role in regulating SPARC promoter activity, then
DNA binding would correlate with promoter activity. To test this hypothesis, these
mutations were made in the context of the full-length (-1409/+28) SPARC promoter.
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Even though we were able to show increased DNA binding in vitro by mutating the AP-1
site to a consensus context, this did not result in an increase in SPARC promoter activity
in c-Jun/MCF7 cells (Fig. 20). In addition, the mutation which decreased AP-1 binding
had no significant effect on SPARC promoter activity. These results suggest that the
-1051/-1045 site was not required for c-Jun responsiveness and prompted us to examine
the extent to which any of the three AP-1 sites were required.
This question was addressed by analyzing a truncated promoter construct in
which -1300 nucleotides (-1409 to -121) were deleted. This resulted in removal of all
obvious AP-1 binding sites. The results presented in Fig. 21 demonstrate that the
truncated -120/+28 SPARC promoter retains -85% of the activity in c-Jun/MCF7 cells
when compared to the full-length (-1409/+28) construct. These results suggest two
things: 1.) that the major c-Jun responsive region lies within this 148 base pair sequence
and 2.) that the AP-1 sites are dispensable for c-Jun responsiveness.
In order to more precisely map the c-Jun responsive region, an additional SPARC
promoter deletion mutant was generated. The results presented in Fig. 22 demonstrate
that the region between -120 and -70 is required for c-Jun responsiveness. This result is
consistent with a previous study which indicated that activation and/or repression is
regulated by DNA sequences in the region from -120 to -70 (129). Furthermore, this is
the same region previously shown to be required for downregulation of the chicken and
human SPARC promoter by v-Jun in primary chicken embryo fibroblasts (130). Since
the AP-1 sites were dispensable for c-Jun responsiveness, we hypothesized that another
sequence specific transcription factor may confer DNA binding. The presence of a
guanine and cytosine (GC) rich sequence between -120 and -70 suggested that Sp family
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proteins may bind to this region. Spl binds GC rich sequences in TATA-less promoters
and can play a dual role as an activator or repressor depending on the context (158, 230,
231). Furthermore, c-Jun and Spl cooperate resulting in activation of other genes such as
p 2 iwAFiicipi, keratin 16 and Vimentin (93, 232-234).
In order to test this hypothesis, gel mobility shift experiments were conducted.
Oligonucleotide competition analysis using a consensus Spl probe demonstrated that two
complexes (complexes 1 and 3) were specifically inhibited (Fig. 23). These complexes
were present in both MCF7 and c-Jun/MCF7 nuclear extracts supporting the idea that
Spl may play a dual role by binding to this region. Furthermore, chromatin
immunoprecipitation (ChIP) analysis demonstrated that Spl, c-Jun and Fra-1 physically
associate with the SPARC promoter locus in intact cells (Fig. 25). Importantly, c-Jun
was not bound at an unrelated locus on chromosome 11 (estrogen receptor alpha locus)
thereby demonstrating specificity (Appendix A, Fig. 47). Based on the ChIP data, we
conclude that SPARC is a bona fide, direct AP-1 target gene.
A recent study examined the role of Sp family proteins in regulating the SPARC
promoter by utilizing Drosophila SL2 cells, which are devoid of endogenous Sp family
genes. In this study, increasing amounts of Spl or Sp3 expression constructs were co
transfected in SL2 cells, along with either the -120/+28 or -70/+28 SPARC
promoter/reporter plasmids (131). The region from -120 to -70 (the previously mapped
c-Jun responsive region) was also shown to be required for Spl responsiveness in this
system (131). These experiments provided the first direct evidence that Sp family
proteins are capable of transactivating the SPARC promoter.
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Similarly, the chicken promoter is also activated in response to Spl in the
Drosophila SL2 system (156). However, when v-Jun was co-expressed, there was an
-60% decrease in Spl dependent transcription (156). This same study showed that v-Jun
mediated repression was via a direct mechanism. Chromatin immunoprecipitation
demonstrated v-Jun protein physically associated with the plasmid template when
transcription was repressed (156). This result is consistent with our current studies where
we are able to demonstrate AP-1 and Spl binding in a chromatinized context in
c-Jun/MCF7 cells (Fig. 25). But, rather than repression, we find that c-Jun activates the
human SPARC promoter in these cells. The reason for this dichotomy regarding SPARC
gene regulation is not known. It is likely that cell type specific factors play a role in this
process since downregulation of SPARC by v-Jun and/or c-Jun is consistent in
fibroblasts, whereas upregulation of SPARC occurs in epithelial cells when c-Jun is
overexpressed.
We propose that Spl serves as a sequence specific DNA binding component at
the SPARC locus. c-Jun and Spl have been shown to interact so it is tempting to
speculate that this may be occurring at the SPARC promoter as a mechanism for
transcriptional activation. The interaction between Spl and c-Jun is mediated by the
glutamine rich region of Spl and leucine zipper region of c-Jun (93, 234). This same
region of Spl interacts with the basal transcription factors including TATA binding
protein, TAF4 and TAF7 (235, 236) . In addition, c-Jun interacts with TFIIB, TAF1 and
TATA binding protein (96, 97). Therefore, it is possible that AP-1 and Spl cooperate to
stabilize assembly of the transcription pre-initiation complex.
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C. Epigenetic Regulation of SPARC Gene Expression

The results obtained in Aim 2 established that a cytosine and guanine rich region
(-120/-70) of the SPARC promoter was required for c-Jun responsiveness. The 5’ carbon
of cytosine in a cytosine-phosphate-guanine (CpG) context has been shown to undergo
methylation (165-167). Importantly, CpG methylation patterns have been shown to
change during tumorigenesis (168-171). The degree of DNA methylation in promoters
tends to be inversely correlated with gene expression levels. The MCF7 and c-Jun/MCF7
model system used in these studies represents transcriptionally “inactive” (MCF7) and
“active” (c-Jun/MCF7) states with respect to SPARC gene expression suggesting active
repression or gene “silencing”. The goal of Aim 3 was to analyze the epigenetic
modifications associated with SPARC gene expression starting with DNA methylation.

The Effect of DNA Methyltransferase Inhibition on SPARC Expression

In order to determine the role of DNA methylation in SPARC gene regulation we
used a pharmacological inhibitor of DNA methyltransferase enzymes, 5-aza-2’
deoxycytidine (5-aza-dC). This reagent has been used to reactivate genes silenced by
DNA methylation (182, 183). The results shown in Fig. 26 demonstrate a dose
dependent increase in steady-state levels of SPARC mRNA in MCF7 cells where SPARC
was previously undetectable. In contrast, 5-aza-dC had no effect on SPARC levels in
c-Jun/MCF7 cells. This suggested that the SPARC promoter is methylated in MCF7
cells, but demethylated in c-Jun/MCF7 cells where SPARC gene expression was already
active. These results are consistent with a recent study in which 5-aza-dC treatment of
lung cancer cells resulted in increased SPARC gene expression (237).
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Next, a time course experiment was conducted in order to determine the kinetics
of SPARC gene activation in response to 5-aza-dC. SPARC transcripts were detectable
as early as 24 hours following initial treatment with 5-aza-dC (Fig. 26). The maximal
effect on SPARC steady state mRNA levels was achieved by 48 hours with no
appreciable increase after that. The MCF7 cells used in this study were previously shown
to have a doubling time of 37 hours (46). Therefore, it would be expected to take 74
hours for a CpG site to become demethylated on both strands of DNA. Therefore, our
results suggest an active, rather than a passive, mechanism of DNA demethylation at the
SPARC promoter.
Since, DNA methylation patterns are faithfully conserved during replication, any
changes are expected to be maintained in daughter cells. Therefore, we wanted to
determine the extent to which demethylation and SPARC gene activation was reversible.
5-aza-dC was removed from the MCF7 growth media and cells were passaged regularly
as subconfluent populations for an additional 60 days (Fig. 26). Our results demonstrate
that SPARC mRNA levels persist long after 5-aza-dC is removed. This suggests that
DNA demethylation may serve as an epigenetic “hit” leading to mitotically heritable gene
activation. These observations are important from a clinical standpoint since DNA
methyltransferase inhibition is being tested as a therapeutic strategy to reactivate silenced
tumor suppressor genes (179). Therefore, it is important to better understand the
pleiotropic effects of DNA methyltransferase inhibitors on genes such as SPARC, which
are capable of contributing to the malignant phenotype.
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M apping SPARC Promoter DNA Methylation

Our previous experiments using 5-aza-dC suggested that DNA methylation plays
a role in regulating SPARC gene expression in MCF7 cells. We hypothesized that this is
a mechanism for transcriptional repression in MCF7 cells and that c-Jun relieves this
repression. This would provide an explanation for the “o ff’ and “on” type of
transcriptional regulation in this model system. In order to determine the extent of
SPARC promoter methylation in each cell line, we analyzed the methylation status of
CpG sequences using Hpall/MspI mapping. The results confirmed that the SPARC
promoter is methylated in MCF7 cells at each of the four Hpall/MspI sites analyzed (Fig.
28). In contrast, the proximal promoter region, including the previously mapped c-Jun
responsive element, becomes demethylated in response to c-Jun overexpression. These
observations were confirmed and extended by using sodium bisulfite modification of
genomic DNA followed by DNA sequencing. Using this approach we were able to
determine the methylation status of 17 CpG residues spanning the entire SPARC
promoter region. As shown in Fig. 28, the SPARC proximal promoter is demethylated in
response to constitutive c-Jun overexpression. Importantly, this demethylation is
localized to the 3’ region of the promoter including the region previously identified as the
c-Jun responsive element.
To our knowledge, this is the first high-resolution map of DNA methylation at the
human SPARC gene promoter. It is unclear why there is a discrete boundary between
proximal and distal promoter methylation in c-Jun/MCF7 cells. We hypothesize that the
physical distance between CpG clusters may buffer, or insulate, the effects occurring in
either region making these cis elements independent of one another. Another possibility
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is that c-Jun/AP-1 specifically targets demethylation to the proximal promoter region. It
is unclear from our current studies whether DNA demethylation preceedes, or occurs
subsequent to, SPARC gene activation. Future studies using an inducible system to
regulate c-Jun expression will be useful in defining the chronology of events leading to
SPARC gene activation.
In contrast to what is known about the process of DNA methylation, the process
of DNA demethylation is poorly understood. There are several mechanisms by which
promoter demethylation and gene reactivation are thought to occur. Evidence suggests
that the methyl binding protein, MBD2, exhibits demethylase activity and may be
responsible for de novo demethylation (238). Alternatively, DNA demethylation can
occur via a passive mechanism. This can occur via DNA methyltransferase inhibition
resulting in sequential loss of methylation on both strands of DNA following two rounds
of replication (239, 240). These mechanisms are not mutually exclusive and future
studies will be needed to determine how the SPARC gene locus becomes demethylated in
response to c-Jun.

The Effect of Methylation on SPARC Promoter Activity and Protein/DNA
Interactions

Next, we sought to determine the extent to which DNA methylation plays a
functional role in SPARC promoter regulation. In order to accomplish this, we
conducted in vitro methylation of the SPARC promoter/luciferase reporter plasmid
followed by transient transfection. The SPARC promoter fragment spanning nucleotides

-120 to +28 was analyzed, since this region becomes demethylated and contains the
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previously mapped c-Jun responsive element. Fortuitously, a single CpG (Hpall site #4)
lies within the c-Jun responsive region (Fig. 31). This allowed for specific methylation of
this site using recombinant Hpall methylase while leaving other CpGs in the SPARC
proximal promoter region unmodified.
As shown in Fig. 31, methylation of Hpall site #4 resulted in a 75% reduction in
SPARC promoter activity in response to c-Jun. Since overexpression of c-Jun promotes
demethylation at the endogenous SPARC locus, it is tempting to speculate that the
residual promoter activity in c-Jun/MCF7 cells is due to progressive demethylation of the
in vitro methylated plasmid over the 48 hour transfection period. This could be
addressed in future studies by analyzing the degree to which methylation is retained on
the transfected, in vitro methylated plasmid DNA template. By comparing the
methylation status over time, it would be possible to determine whether demethylation, in
this context, occurs in c-Jun overexpressing cells and the extent to which this might
correlate with relative SPARC promoter activity.
Our data supports a model where SPARC promoter methylation is not simply a
byproduct of transcriptional repression. Instead, DNA methylation of the c-Jun
responsive element is sufficient to repress transactivation. In addition, our studies
suggest an explanation for previous observations in which transiently transfected SPARC
promoter constructs were active in HeLa and HepG2 cells, but endogenous SPARC gene
expression was undetectable (129). We hypothesize that the endogenous genomic locus
may be methylated in these cells in contrast to the transfected plasmid DNA.
Next, we examined the effect of in vitro methylation on protein/DNA interactions
by gel mobility shift analysis. We used the same gel shift probe (-120/-83) which
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demonstrated Sp family binding activity in order to determine if specific methylation at
Hpall site #4 altered the protein binding pattern (Fig. 33). Previous studies have shown
that Spl/Sp3 DNA binding are not affected by CpG methylation (192). In agreement
with these studies, our results demonstrate that similar protein/DNA complexes are
observed in the presence, or absence, of Hpall methylation. Based on our previous gel
mobility shift data (Fig. 23) and chromatin immunoprecipitation analysis (Fig. 25) we
attribute this binding to Sp family proteins. Taken together, our data supports the
hypothesis that Spl is present at the SPARC locus, regardless of the methylation status.
This suggests that Spl participates in a repression complex in the absence of c-Jun
overexpression and then becomes an activator of SPARC transcription in the presence of
c-Jun.
How can Spl play dual roles in regulating SPARC gene transcription? One
candidate protein which may act as a bifunctional modulator of Spl is MCAF (MBD1
chromatin associated factor). MCAF has been shown to function as a both an activator as
well as a repressor of gene transcription (241). As the name implies, MCAF can
physically associate with the methyl binding protein, MBD1, but has also been shown to
bind Spl as well (241). Interestingly, the murine homolog of MCAF, mAM, was
previously shown to interact with the murine ATFa, a known Jun dimerization partner
(242). This interaction between MCAF and ATFa correlates with recruitment of the
basal transcription machinery components TFIIE, TFIIH and RNA polymerase II (242).
Based on these studies, it is tempting to speculate that MCAF may be a missing link in
deciphering the precise mechanism of SPARC gene regulation by Spl and AP-1. We
envision a scenario where Spl/MBDl/MCAF exist in a ternary complex at the SPARC
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promoter and mediate repression in MCF7 cells. In this case MCAF would confer
repressor function to Spl. Then, following c-Jun overexpression, AP-1 may compete
with MBD1 resulting in a Spl/AP-l/M CAF activation complex. Further biochemical
characterization will be required to confirm this hypothesis.

Analysis of DNA Methyltransferase Expression in MCF7 and c-Jun/MCF7 Cells

As a follow up study, we explored the possibility that c-Jun alters the expression
of DNMT 1, DNMT3a and/or DNMT3b resulting in aberrant genomic DNA methylation
patterns. In support of this hypothesis, previous studies have shown that c-Jun and c-Fos
stimulate DNMT1 expression (94, 243). Therefore, we examined the relative expression
levels of DNA methyltransferase genes in MCF7 and c-Jun/MCF7 cells.
As shown in Appendix A, Fig. 43, c-Jun overexpression in MCF7 cells induces a
modest increase in DNMT1 steady state mRNA levels. However, the most notable
difference observed was in the expression pattern of multiple DNMT3b isoforms. By
using an oligonucleotide primer pair flanking potential 3’ DNMT3b mRNA splice sites,
several known splice variants are detectable in MCF7 and c-Jun/MCF7 cells.
Interestingly, increased expression of DNMT3b isoforms has been demonstrated in
human cancers (244, 245). Specifically, DNMT3b4 expression correlates with DNA
hypomethylation at pericentromeric repeats and is associated with chromosome
instability in hepatocellular carcinomas (246). In addition, MCF7 cells express primarily
DNMT3b2, whereas T24 bladder cancer cells express mainly the DNMT3b3 isoform
(247). Several of these alternatively spliced transcripts are expected to yield catalytically
inactive isoforms suggesting they may have other, as of yet, undetermined roles in DNA
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methylation (178, 248). Taken together, the data suggests that altered expression of
DNMT3b isoforms may play a role in regulating SPARC promoter methylation.
Exploring this possibility will be the focus of future studies.

Analysis of Histone Modifications at the SPARC Promoter Locus

DNA methylation changes are known to correlate with post-translational
modification of histone “tails” (249, 250). Therefore, we used chromatin
immunoprecipitation to analyze specific histone modifications at the SPARC promoter
locus. Characterization of the proximal promoter region in c-Jun/MCF7 cells revealed
changes known to be associated with gene activation (Fig. 35). For example, we
observed an increase in acetylated histone H3 and H4 as well as methylation of histone
H3, specifically at lysine 4. The fact that there is a basal level of acetylated histones and
H3-K4 methylation in empty vector control/MCF7 cells suggests that this is a
euchromatic locus, even though gene expression is not active in these cells. In support of
this idea, we did not detect tri-methylation of histone H3 at lysine 9, in either cell line,
further suggesting that the locus does not reside in a heterochromatic region. To our
knowledge, this is the first analysis of histone modifications at the SPARC promoter.
These modifications constitute the “histone code” at the locus.
The histone “code”, together with DNA methylation patterns, comprise a larger
epigenetic “code” recognized by transcriptional regulators. We envision a scenario
where chromatin modifying proteins are specifically targeted to the c-Jun responsive
region of the SPARC promoter. The net result of such recruitment is transformation of
the locus from a repressed state to an activated state. In addition, it is likely that these
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c-Jun induced changes antagonize the repression machinery and serve to maintain the
activated state of SPARC gene transcription. For example, both AP-1 and Spl have been
shown to interact with the histone acetyltransferase CBP/p300 (99, 251). Recruitment of
CBP/p300 to the SPARC proximal promoter region would be expected to result in an
increase in the level of acetylated histones at the locus. This hypothesis could be tested
by chromatin immunoprecipitation analysis of the SPARC promoter using a CBP/p300
specific antibody.
A similar mechanism of targeted recruitment may account for elevated levels of
H3-K4 dimethylation at the SPARC promoter (Fig. 35). In support of this idea, a recent
study demonstrated that the H3-K4 specific methyltransferase, SET7/9, is involved in
regulation of the AP-1 target gene, collagenase (252). This study showed that SET7/9
physically associates with the collagenase promoter at low levels prior to collagenase
gene induction and then becomes enriched at the locus concomitant with AP-1 binding
and transcriptional activation (252). A similar scenario may explain the basal level of
H3-K4 methylation observed in MCF7 cells. Therefore, the presence of this modification
may render the locus “poised” for activation prior to c-Jun induction.
A final experiment was conducted to demonstrate the extent to which histone
acetylation/deacetylation contributes to SPARC gene regulation. MCF7 cells were
treated with the histone deacetylase inhibitor trichostatin A (TSA) and SPARC steady
state mRNA levels determined by semi-quantitative RT-PCR. TSA is a well
characterized, non-competitive inhibitor of histone deacetylase enzymes (222). Previous
studies have shown reactivation of silenced genes in response to TSA (223, 224).
Depending on the context, treatment with TSA and 5-aza-dC can result in synergistic
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activation of gene expression (191, 223, 224). The results presented in Figure 36 show
that SPARC expression was increased only by 5-aza-dC and not TSA, alone, or in
combination with 5-aza-dC. This result demonstrates that, in MCF7 cells, repression of
SPARC gene transcription occurs via a TSA insensitive mechanism. This is consistent
with the relative enrichment of acetylated histones at the SPARC locus in MCF7 cells
and suggests that maintenance of the repressed state is HD AC independent. This
strengthens the argument that, in MCF7 cells, DNA methylation is the dominant
epigenetic modification regulating SPARC gene expression.

Analysis of c-Jun Induced Epigenetic Changes at the Human Vimentin and
Estrogen Receptor Alpha Gene Loci

In our MCF7 model system, expression of another gene, vimentin, is regulated in
an “o ff’ and “on” manner similar to SPARC (51). Vimentin is an intermediate filament
protein expressed in cells of mesenchymal origin and has, therefore, been used as a
marker for epithelial-to-mesenchymal transition observed in invasive breast cancers
(253). An early study demonstrated that AP-1 was responsible for serum and PMA
(phorbol 12-myristate 13-acetate) inducibility of vimentin gene expression (254). This
study also showed that tandem AP-1 elements located -700 base pairs upstream of the
transcription start site were necessary and sufficient for this effect (254). These sites
were subsequently shown to exhibit AP-1 binding in vitro and a recent study
demonstrated that AP-1 and Spl cooperate resulting in synergistic activation of the
human vimentin promoter (234, 254). However, there has been no direct evidence that
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AP-1 and/or Spl physically associate with the vimentin promoter in an endogenous,
genomic context.
In contrast to SPARC, the vimentin promoter is a classical CpG island with 56
CpG sequences over a 600 base pair region surrounding the tandem AP-1 sites (Appendix
A, Fig. 44). The results presented in Appendix A, Fig. 44 demonstrate that this locus is
almost completely methylated in empty vector control/MCF7 cells where transcription is
repressed. However, there is a dramatic and widespread loss of DNA methylation in
response to c-Jun overexpression. In contrast to the SPARC gene locus, the widespread
demethylation of the vimentin promoter CpG island demonstrates that c-Jun is capable of
inducing more than just localized changes in DNA methylation during target gene
activation. In addition, chromatin immunoprecipitation analysis demonstrated that c-Jun
and Fra-1 physically associate with the vimentin promoter in the demethylated state
(Appendix A, Fig. 45). These experiments provide the first direct evidence that vimentin
is a direct AP-1 target gene. It is likely that in this case, c-Jun and Fra-1 utilize two
adjacent AP-1 sites since they are in a consensus context and this region was previously
shown to be required for AP-1 responsiveness. Similar to what we observed at the
SPARC locus, Spl was present at the vimentin promoter under conditions where
transcription was repressed or activated. This further suggests a bi-functional role for
Spl in transcriptional activation.
In contrast to the SPARC locus, chromatin immunoprecipitation analysis of the
vimentin promoter in MCF7 cells revealed histone modifications consistent with a
heterochromatic, transcriptionally silent locus (Appendix A, Fig. 45). One of the most
striking changes induced by c-Jun was loss of histone H3-lysine 9 tri-methylation, a
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modification strictly associated with classic epigenetic gene silencing. This result also
serves as a positive control, demonstrating that the negative result obtained at the SPARC
promoter using the anti-tri-methyl histone H3-K9 antibody (Fig. 35) is a “real” negative
result.
Based on characterization of epigenetic changes at the SPARC and vimentin gene
loci, we wanted to determine if any c-Jun target genes were regulated in an opposite
manner. Therefore, we chose to examine the estrogen receptor alpha (ERa) gene locus.
ERa expression is “on” in growth factor dependent MCF7 cells and “off* in estrogen
independent and tamoxifen resistant c-Jun/MCF7 cells (46). The ERa locus is known to
become hypermethylated in invasive, ERa negative, breast cancer cells and this correlates
with loss of ERa expression (183, 255, 256). However, the mechanisms driving this
process are unclear. In order to characterize the methylation status of the ERa promoter
in our model system, we conducted Hpall/MspI mapping as shown in Appendix A,
Fig. 46. The results demonstrate a localized hypermethylation in response to c-Jun
overexpression. Specifically, the CpG rich region immediately 3 ’ of the promoter “A”
transcription start site becomes completely methylated and this correlates with
transcriptional repression. This is in agreement with the current paradigm where the
degree of promoter methylation inversely correlates with the level of gene transcription.
Next, we conducted chromatin immunoprecipitation analysis in order to
determine the histone modifications and protein/DNA interactions at the estrogen
receptor alpha locus. The results presented in Appendix A, Fig. 47 show that Spl is
present at the locus only in MCF7 cells when transcription is active. Importantly, this
demonstrates that Spl is not ubiquitously present under all conditions tested in our

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

143

studies. Interestingly, c-Jun and Fra-1 are not associated with the ERa locus, at least not
in the hypermethylated region analyzed by ChlP. This suggests that ERa may be an
indirect AP-1 target gene. In addition, our analysis revealed hypoacetylation of histone
H3 in c-Jun/MCF7 cells during the repressed state and enrichment of methylated histone
H3 at lysine 4 in MCF7 cells during active transcription. These changes are in agreement
with the current paradigm that histone acetylation and H3-K4 methylation directly
correlate with the relative level of gene transcription.
Taken together, our analysis of the SPARC, vimentin and estrogen receptor alpha
gene loci highlight the diverse mechanisms by which c-Jun regulates target gene
expression. Importantly, these studies were conducted in a biologically relevant model
system which recapitulates the phenotypic changes associated with malignant breast
cancer progression.
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CHAPTER V
CONCLUSIONS

Our hypothesis was that c-Jun binds to the SPARC promoter leading to an
increase in SPARC mRNA and protein and a concomitant change to a pro-invasive cell
phenotype. Our objectives were 1.) to determine the contribution of SPARC to c-Jun
induced phenotype in a MCF7 breast cancer model system and 2.) to determine the
mechanism(s) by which c-Jun regulates SPARC gene expression. The results described
in Chapter III of this dissertation have led us to propose the following conclusions:

1.) Overexpression of SPARC in MCF7 cells leads to a statistically significant
(P= <0.05) decrease in cell proliferation rate.

2.) Overexpression of SPARC, in the absence of c-Jun overexpression, was not sufficient
to induce MCF7 cell motility and invasion.

3.) Inhibition of SPARC expression in c-Jun/MCF7 cells results in a statistically
significant (P= <0.05) decrease in cell motility and invasion.

4.) Three AP-1 like sites (-1051/-1045, -868/-862, -241/-235) in the SPARC promoter
are dispensable for c-Jun responsiveness.
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5.) The SPARC promoter region spanning nucleotides -120 to -70 contains the c-Jun
responsive element (JRE) required for maximal promoter activation in c-Jun/MCF7 cells.

6 .) Spl and AP-1 (c-Jun and Fra-1) are present at the SPARC proximal promoter region
in vivo in c-Jun/MCF7 cells where SPARC is expressed. In MCF7 cells, where SPARC
expression is undetectable, only Spl is present at the SPARC promoter.

7.) Treatment of MCF7 cells with the DNA methyltransferase inhibitor, 5-aza2’deoxycytidine (5-aza-dC), results in reactivation of SPARC gene expression, whereas
in c-Jun/MCF7 cells, there is no effect on SPARC expression.

8.) Overexpression of c-Jun in MCF7 cells results in localized demethylation of the
SPARC proximal promoter region.

9.) In vitro methylation of a single Hpall site between -120/-70 of the SPARC promoter
abrogates c-Jun responsiveness.

10.) Hypermethylation and hyperacetylation of histone H3 lysine 4 correlates with
increased SPARC expression in response to c-Jun.

11.) In MCF7 cells, repression of SPARC gene transcription is maintained by a histone
deacetylase independent mechanism.
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These conclusions have led us to propose the following model of SPARC gene
regulation:
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Fig. 37. Proposed model of c-Jun/AP-1 transcriptional regulation of SPARC
gene expression. The size of the arrow represents transcription level in each cell
line. (HAT) histone acetyltransferase, (MCAF) MBD1 chromatin associated factor,
(DNMT1) DNA methyltransferase, (MBD) methyl binding protein, (Ac) acetylation,
(Me) methylation.
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Fig. 38. Analysis of in vitro cell motility and invasion demonstrated by
JunD/MCF7 stable cell lines. A, Quantitation of cell motility assays done on
gelatin coated membranes over a 4 hour incubation period. B, Quantitation
of cell invasion assays conducted on Matrigel™ coated membranes over a
period of 4 hours. All values are expressed as the number of stained cells per
high power field.
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Fig. 39. AP-1 DNA binding activity in nuclear extracts from empty vector
control/MCF7, JunD/MCF7 or c-Jun/MCF7 stable cell lines. A radiolabeled
oligonucleotide probe corresponding to a consensus AP-1 site from the intron 1
region of the human Fra-1 gene was used in gel shift reactions (25,000cpm). Anti
c-Jun, anti JunD, anti Fra-1 or anti p i 30 (negative control) antibodies were
incubated with the radiolabeled probe and nuclear extracts as indicated.
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Fig. 40. Determination of recombinant adenoviral titer. Virus was
propagated as described in Chapter II. HEK293 cells were infected with the
indicated dilutions of virus stock. Cells were assayed 48 hours later for
production of adenovirus hexon protein using the Clontech Rapid Titer™ Kit
as described in Chapter II.
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Fig. 41. Infection of c-Jun/MCF7 cells with recombinant
adenovirus expressing beta-galactosidase. Magnification= 10X
objective.
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Cell Proliferation Rate of JunD/MCF7 Stable Cell Lines
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Fig. 42. Effect of stable JunD expression on MCF7 cell proliferation. Cell
proliferation rates were determined by MTT assay as described in Chapter IF The
indicated cell lines were plated at the same density in 96-well plates. Samples were
assayed at 19, 43, 65 and 87 hours. Optical densities were determined using a
microtiter plate reader where A= absorbance at 570nm wavelength.
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Fig. 43. Semi-quantitative RT-PCR analysis of steady state DNA
methyltransferase levels in MCF7 and c-Jun/MCF7 cell lines. DNMT3b
RT-PCR primers flank the alternatively spliced 3’ coding region.
Individual DNMT3b amplicons (upper most and lower most bands) were
gel purified and identified by DNA sequencing. DNMT3b-4 and
DNMT3b-5 identities are inferred based on amplicon size compared to
published reports (242). The 18S ribosomal subunit gene serves as an
invariantly expressed, internal control.
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Fig. 45. Chromatin immunoprecipitation analysis of the vimentin gene locus in MCF7 and c-Jun/MCF7 stable
cell lines. A, Schematic representation of the human vimentin genomic locus. Lollypops denote the location of CpG
sequences. Arrows denote the genomic region amplified by PCR during chromatin immunoprecipitation analysis.
B, Results of chromatin immunoprecipitation analysis using the following antibodies: (Ac-H3) anti diacetylated
histone H3, (Ac-H4) anti tetraacetylated histone H4, (diMe-H3-K4) anti dimethyl histone H3 at lysine 4, (triMe-H3K9) trimethyl histone H3 at lysine 9, anti c-Jun, anti Fra-1, anti Spl, (NAC) no antibody control. ( — )= no template
added negative control for PCR reactions.
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Fig. 46. The estrogen receptor alpha gene locus is hypermethylated in
c-Jun/MCF7 cells. A, Schematic representation of the a region of the human
estrogen receptor alpha gene locus. Arrows indicate transcription start sites.
B, Hpall/MspI mapping of DNA methylation. Genomic DNA isolated from
either MCF7 or c-Jun/MCF7 cells was digested with Hpall, Mspl or left
undigested (UC). Following digestion, PCR was performed using
oligonucleotide primer pairs flanking the Hpall/MspI sites. (—) denotes the
negative control PCR reaction in which DNA template was omitted.
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Fig. 47. Chromatin immunoprecipitation analysis of the estrogen
receptor alpha gene locus in MCF7 and c-Jun/MCF7 stable cell lines. A,
Schematic representation of the estrogen receptor alpha genomic locus. The
large arrows denote potential transcription start sites. The smaller arrows
denote the genomic region amplified by PCR during chromatin
immunoprecipitation analysis. Lollypops denote the location of Hpall/MspI
sites. (+1) denotes the major transcription start site. B, Results of
chromatin immunoprecipitation analysis using the following antibodies:
(Ac-H3) anti diacetylated histone H3, (Ac-H4) anti tetraacetylated histone
H4, (diMe-H3-K4) anti dimethyl histone H3 at lysine 4, (triMe-H3-K9)
trimethyl histone H3 at lysine 9, anti c-Jun, anti Fra-1, anti Spl, (NAC) no
antibody control. (— )= no template added negative control for PCR
reactions.
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